OMIM Entry - # 176270 - PRADER-WILLI SYNDROME PWS PDF

27/5/2014 OMIM Entry - # 176270 - PRADER-WILLI SYNDROME; PWS
http://omim.org/entry/176270?search=prader-willi&highlight=praderwilli 1/27
SNOMEDCT: 89392001 ICD10CM: Q87.1 ICD9CM: 759.81
#176270
PRADER-WILLI SYNDROME; PWS
Alternative titles; symbols
PRADER-LABHART-WILLI SYNDROME
Other entities represented in this entry:
PRADER-WILLI SYNDROME CHROMOSOME REGION, INCLUDED; PWCR, INCLUDED
PRADER-WILLI-LIKE SYNDROME ASSOCIATED WITH CHROMOSOME 6, INCLUDED
Phenotype-Gene Relationships
Clinical Synopsis
TEXT
A number sign (#) is used with this entry because of evidence that Prader-Willi syndrome (PWS) is in effect a contiguous gene syndrome resulting from
deletion of the paternal copies of the imprinted SNRPN gene (182279), the NDN gene (602117), and possibly other genes within the chromosome region
15q11-q13.
Description
Prader-Willi syndrome is characterized by diminished fetal activity, obesity, muscular hypotonia, mental retardation, short stature, hypogonadotropic
hypogonadism, and small hands and feet. It can be considered to be an autosomal dominant disorder and is caused by deletion or disruption of a gene or
several genes on the proximal long arm of the paternal chromosome 15 or maternal uniparental disomy 15, because the gene(s) on the maternal
chromosome(s) 15 are virtually inactive through imprinting. Horsthemke and Wagstaff (2008) provided a detailed review of the mechanisms of imprinting
of the Prader-Willi/Angelman syndrome (105830) region.
See also the chromosome 15q11-q13 duplication syndrome (608636), which shows overlapping clinical features.
Clinical Features
The original paper by Prader et al. (1956) described the full clinical picture.
Prenatal
Mothers with prior experience of normal pregnancies almost without exception report distinctly delayed onset and reduced fetal activity during the
pregnancies involving Prader-Willi children. Obstetricians often fail to detect diminished fetal activity with ultrasound investigation. When reduced fetal
activity is observed, prenatal cytogenetic examination produces normal results because cytogeneticists were not instructed to look for the characteristic
chromosomal changes of PWS (Schinzel, 1986). Alert clinicians should refer CVS material from pregnancies with fetuses that demonstrate poor activity for
molecular diagnosis of the syndrome (see below). Other candidates for prenatal diagnosis of PWS are fetuses of pregnancies in which trisomy 15 or mosaic
trisomy 15 was determined from CVS, and in which subsequent amniocyte or fetal blood examinations disclosed a normal diploid karyotype. Theoretically,
one-third of trisomy 15 fetuses initially with 2 maternal chromosomes 15 and 1 paternal chromosome 15 should give rise to Prader-Willi syndrome patients
exhibiting maternal uniparental disomy (Cassidy et al., 1992; Purvis-Smith et al., 1992; Hall, 1992).
Perinatal
Neonates are profoundly hypotonic, which often causes asphyxia. In addition, there is mild prenatal growth retardation with a mean birth weight of about
6 lbs (2.8 kg) at term, hyporeflexia, poor feeding due to diminished swallowing and sucking reflexes, which in many cases necessitates gavage feeding for
about 3 to 4 months. Cryptorchidism occurs with hypoplastic penis and scrotum in boys and hypoplastic labiae in girls (Stephenson, 1980). Chitayat et al.
(1989) commented on the normal size of hands and feet at birth and in the first year of life.
Miller et al. (1999) described 6 newborns evaluated for hypotonia who were later diagnosed with Prader-Willi syndrome. These newborns lacked the classic
Location Phenotype Phenotype
MIM number
Pheno
map
key
Gene/Locus Gene/Locus
MIM number
15q11.2 Prader-Willi syndrome 176270 3 NDN 602117
15q11.2 Prader-Willi syndrome 176270 3 SNRPN 182279
neonatal features of the syndrome (peculiar cry, characteristic craniofacial features, and clinical evidence of hypogonadism). The authors suggested that
specific genetic testing for PWS be considered for all neonates with undiagnosed central hypotonia even in the absence of the other major features of the
syndrome.
Oiglane-Shlik et al. (2006) studied 5 newborns with hypotonia, poor arousal, weak or absent cry, and no interest in food, in whom PWS was confirmed by
the abnormal methylation test. All had a distinctive facial appearance, with high prominent forehead, narrow bifrontal diameter, downturned corners of the
mouth, micrognathia, and dysplastic ears. Three neonates had a high-arched palate, and 4 had arachnodactyly. In the first few days of life, 4 of the 5
patients demonstrated a peculiar position of the hands, with the thumb constantly adducted over the index and middle finger. All 5 patients had transient
bradycardia, thermolability, and acrocyanosis; and 3 also showed marked skin mottling, as previously reported by Chitayat et al. (1989).
Infancy and Childhood
Feeding difficulties generally improve by the age of 6 months. From 12 to 18 months onward, uncontrollable hyperphagia causes major somatic as well as
psychologic problems. Diminished growth is observed in the majority of infants (Butler and Meaney, 1987). Small hands with delicate and tapering fingers
and small feet (acromicria) are seen in most infants and adolescents; hand and foot sizes correlate well with length, but not with age, and foot size tends to
be lower than hand size. However, patients of normal height tend to have normally sized hands (Hudgins and Cassidy, 1991). The face is characterized by
a narrow bifrontal diameter, almond-shaped eyes (often in mild upslanted position), strabismus, full cheeks, and diminished mimic activity due to muscular
hypotonia. Plethoric obesity becomes the most striking feature. From the age of about 6 years onward, many children present scars from scratching due to
itching, and later, almost all show abdominal striae.
Depigmentation relative to the familial background is a feature in about three-quarters of the patients. Butler (1989), Hittner et al. (1982), and several
authors remarked that this sign is confined to cases with deletions and absent in those with maternal disomy 15. Phelan et al. (1988) presented a black
female child with oculocutaneous albinism, PWS, and an interstitial deletion of 15q11.2. Patients with classic albinism (203100) have misrouting of optic
fibers, with fibers from 20 degrees or more of the temporal retina crossing at the chiasm instead of projecting to the ipsilateral hemisphere. Misrouting can
result in strabismus and nystagmus. Because patients with PWS have hypopigmentation and strabismus, Creel et al. (1986) studied 6 patients, selected for a
history of strabismus, with pattern-onset visual evoked potentials on binocular and monocular stimulation. Of the 4 with hypopigmentation, 3 had
abnormal evoked potentials indistinguishable from those recorded in albinos. The 2 with normal pigmentation had normal responses. Wiesner et al. (1987)
found that 14 of 29 patients with PWS had ocular hypopigmentation. There was possible correlation between hypopigmentation and a deletion of 15q.
MacMillan et al. (1972) described 2 unrelated girls with the features of PWS who additionally showed precocious puberty. They suggested that this is a
variant and that a hypothalamic disturbance is responsible for this disorder. Hall and Smith (1972) pointed out narrow bifrontal cranial diameter as a
feature. Hall (1985) pointed to a possibly increased risk of leukemia in PWS.
A frequent feature generally overlooked is thick saliva at the edges of the mouth. Patients tend to be relatively insensitive to pain (including that caused by
obtaining blood samples)(Prader, 1991).
Eiholzer et al. (1999) presented data on body composition and leptin (164160) levels of 13 young, still underweight children and 10 older overweight
children with Prader-Willi syndrome. Both groups showed elevated skinfold standard deviation scores for body mass index and elevated body mass index-
adjusted leptin levels, suggesting relatively increased body fat even in underweight children. Leptin production appeared to be intact. The authors
concluded that body composition in PWS is already disturbed in infancy, long before the development of obesity.
Van Mil et al. (2001) compared body composition in 17 patients with PWS with 17 obese control patients matched for gender and bone age. In children
with PWS, adiposity was associated with reduced fat-free mass, and extracellular-to-intracellular water ratio was increased. Both findings are related to
growth hormone (GH; 139250) function and physical activity. Bone mineral density, especially in the limbs, tends to be reduced in patients with PWS and
is related to growth hormone function.
Gunay-Aygun et al. (2001) reviewed the sensitivity of PWS diagnostic criteria and proposed revised criteria for DNA testing. From birth to 2 years any
infant with hypotonia and poor suck should have DNA testing for the PWS deletion. From age 2 to 6 years any child with hypotonia and a history of poor
suck and global developmental delay should have DNA testing. From 6 years to 12 years any child with history of hypotonia and poor suck, global
developmental delay, and excessive eating with central obesity should be tested for PWS.
Adolescence and Adulthood
Greenswag (1987) reported on a survey of 232 adults with PWS, ranging in age from 16 to 64 years. Of 106 patients whose chromosomes were analyzed,
54 had an abnormality of chromosome 15, primarily a deletion. Physical characteristics, health problems, intelligence, psychosocial adjustment, and impact
on the family were reviewed. Emotional lability, poor gross motor skills, cognitive impairment, and insatiable hunger were especially remarkable features.
Olander et al. (2000) pointed to the occurrence of 3 PWS phenotypes: patients with paternal deletions have the typical PWS phenotype; patients with
maternal UPD have a slightly milder phenotype with better cognitive function; and patients with maternal UPD and mosaic trisomy 15 have the most
severe phenotype with a high incidence of congenital heart disease. They described a patient with the severe phenotype with maternal isodisomy rather
than the more common maternal heterodisomy. They concluded that the more severe PWS phenotype was due to trisomy 15 mosaicism rather than to
homozygosity for deleterious chromosome 15 genes.
In contrast to infants, adults invariably are small compared to their family members (Butler and Meaney, 1987). Due to high caloric intake, alimentary
diabetes frequently sets in during or soon after the period of puberty. Puberty itself is diminished in PWS patients of both sexes. Adolescents and young
adults often require digitalization because of cardiac insufficiency; however, it has been shown that substantial weight reduction relieves the need of cardiac
therapy. Any attempt to reduce food intake in these adolescents often leads to serious psychologic and behavioral problems, and in some children, the
situation in their home environment becomes intolerable (Curfs et al., 1991). Patients rarely survive beyond 25 to 30 years of age, the cause of death being
diabetes and cardiac failure. However, if strict weight control is achieved, both diabetes and cardiac failure are greatly reduced and survival is either not or
only mildly reduced. Johnsen et al. (1967) studied 7 mentally retarded patients, aged 4 to 19 years. Studies showed that fat synthesis from acetate during
fasting was 10 times greater in patients than in unaffected sibs, and that hormone-stimulated lipolysis was depressed. These workers suggested that the
condition is comparable to the genetic obese-hyperglycemic mouse. Since during fasting substrate continues to be used for new fat and lipolysis is deficient,
survival depends on a continuous supply of exogenous calories. The abundant fat, muscle hypotonia, and small feet and hands are exactly the opposite of
the sparse fat, muscle hypertrophy, and large hands and feet in Seip syndrome (269700).
Hoybye et al. (2002) studied the clinical, genetic, endocrinologic, and metabolic findings in 10 male and 9 female adult PWS patients (mean age, 25 years).
The PWS karyotype was demonstrated in 13 patients. The mean BMI was 35.6 kg/m2, and total body fat was increased. Two-thirds were biochemically
hypogonadal. Fifty percent had severe GH deficiency. Four were hypertensive. One patient had heart failure and diabetes. Impaired glucose tolerance was
seen in 4 patients, elevated homeostasis model assessment index in 9, and modest dyslipidemia in 7. IGF-binding protein-1 (146730) correlated negatively
with insulin (176730) levels. Four patients had osteoporosis, and 11 had osteopenia. There was no significant difference between the group with the PWS
karyotype and the group without the karyotype in age, BMI, waist-to-hip ratio, percent body fat, insulin values, homeostasis model assessment index, or
lipid profile, except for lipoprotein(a) (152200), which was significantly higher in the group with the negative karyotype. Hoybye et al. (2002) concluded
that the risk factors found predicting cardiovascular disease were secondary to GHD and emphasized the importance of evaluating treatment of GHD in
adults with PWS.
Curfs et al. (1991) concluded that PWS patients score better on visual motor discrimination skills than on auditory verbal processing skills.
Wise et al. (1991) described 5 patients with PWS who experienced recurrent hyperthermia in infancy. On the basis of these patients and other reports of
abnormal temperature regulation in PWS patients, particularly hypothermia with exposure to cold, they concluded that defects in temperature regulation
may be a manifestation of hypothalamic dysfunction in PWS. On the other hand, Cassidy and McKillop (1991) concluded on the basis of a survey that
clinically significant abnormal temperature control is not a common finding in this disorder. Similarly, Williams et al. (1994) concluded on the basis of a
survey that the prevalence of febrile convulsions, fever-associated symptoms, and temperature less than 94 degrees F were not unique to PWS but can occur
in any neurodevelopmentally handicapped individual and do not necessarily reflect syndrome-specific hypothalamic abnormalities.
Individuals with Prader-Willi syndrome manifest severe skin picking behavior. Bhargava et al. (1996) described 3 adolescent patients in whom an extension
of this behavior to rectal picking resulted in significant lower gastrointestinal bleeding and anal rectal disease. Recognition of this behavior is important to
avoid misdiagnosing inflammatory bowel disease in PWS patients.
Wharton et al. (1997) presented 6 patients with PWS with dramatic acute gastric distention. In 3 young adult women with vomiting and apparent
gastroenteritis, clinical course progressed rapidly to massive gastric dilatation and gastric necrosis. One patient died of overwhelming sepsis and
disseminated intravascular coagulation. In 2 children, gastric dilatation resolved spontaneously. Gastrectomy was performed in 2 cases; in 1, gastrectomy
was subtotal and distal, whereas in the other, gastrectomy was combined with partial duodenectomy and pancreatectomy. All specimens showed ischemic
gastroenteritis. There was diffuse mucosal infarction with multifocal transmural necrosis.
From a study of 10 African Americans with PWS, Hudgins et al. (1998) pointed out that the clinical features differ from those of white patients. Growth is
less affected, hand and foot lengths usually are normal, and the facies are atypical; as a result, PWS may be underdiagnosed in this population.
Lindgren et al. (2000) studied the microstructure of eating behavior in patients with PWS and compared it with that of members of obese and normal
weight control groups of the same age. PWS patients had a mean age of 10 +/- 4 years, while the control groups were 12 +/- 3 years (normal weight) and 12
+/- 4 years (obese). Subjects with PWS had a longer duration of eating rate compared with members of both obese and normal weight groups. In subjects
with PWS, 56% of the eating curves were non-decelerating, compared with 10% of the normal weight group and 30% of the obese group. Lindgren et al.
(2000) concluded that the eating behavior found in subjects with PWS might be due to decreased satiation rather than increased hunger.
Nagai et al. (2000) reported standard growth curves for height and weight among Japanese children with Prader-Willi syndrome. No difference in height
was seen between those with and those without chromosome 15q deletion.
Cassidy et al. (1997) personally examined and studied using molecular techniques 54 individuals with PWS to determine whether there are phenotypic
differences between patients with the syndrome due to deletion (present in 37) or uniparental disomy (present in 17) as the mechanism. Previously
recognized increased maternal age in patients with UPD and increased frequency of hypopigmentation in those with deletion were confirmed. Although
the frequency and severity of most other manifestations of PWS did not differ significantly between the 2 groups, those with UPD were less likely to have a
'typical' facial appearance. In addition, this group was less likely to show some of the minor manifestations such as skin picking, skill with jigsaw puzzles,
and high pain threshold. Females and those with UPD were also older, on average.
Gunay-Aygun et al. (2001) proposed new revised criteria for DNA testing for individuals in adolescence and adulthood. Anyone with cognitive impairment
(usually mild mental retardation), excessive eating with central obesity, and hypothalamic hypogonadism, and/or typical behaviors, including temper
tantrums and obsessive-compulsive features, should be referred for DNA testing for PWS.
Among 25 patients with PWS aged 18 years or older, Boer et al. (2002) found that 7 (28%) had severe affective disorder with psychotic features, with a
mean age of onset of 26 years. The 7 affected persons, all aged 28 years or older, included all 5 with disomies of chromosome 15, 1 with a deletion in this
chromosome, and 1 with an imprinting center mutation in the same chromosome. They postulated that in PWS, an abnormal pattern of expression of a
sex-specific imprinted gene on chromosome 15 is associated with psychotic illness in early adult life.
Vogels et al. (2004) detailed the psychopathologic manifestations of 6 adults with PWS and a history of psychotic episodes. Characteristics of the psychotic
disorder included early and acute onset, polymorphous and shifting symptoms, psychiatric hospitalization along with precipitating stress factors, and a
prodromal phase of physiologic symptoms.
To evaluate the risk of cancer in patients with PWS, Davies et al. (2003) conducted a retrospective questionnaire survey of its occurrence among patients
registered with the PWS Association compared with cases in the general US population based on the SEER program. The median age of 1,024 PWS
patients was 19.0 years (range, 0.1-63 years) with 2 older than age 50. The ratio of observed (8) to expected (4.8) cancers was 1.67 (p = 0.1610; 95% CI =
0.72-3.28). Three myeloid leukemias were confirmed, resulting in a ratio of observed to expected of 40.18 (p = 0.0001; 95% CI = 8.0-117). The authors
speculated that a gene within the 15q11-q13 region may be involved in the biology of myeloid leukemia or that secondary manifestations of PWS, such as
obesity, may be associated with an increased risk of certain cancers.
Wey et al. (2005) described a woman with features consistent with PWS due to a mosaic imprinting defect. Three independent assays revealed a reduced
proportion of nonmethylated SNURF-SNRPN alleles in peripheral blood DNA. Microsatellite analysis and FISH revealed apparently normal chromosomes
15 of biparental origin. Wey et al. (2005) estimated that approximately 50% of the patient's blood cells had an imprinting defect. Apart from a rather
normal facial appearance, the proband had typical features of PWS in terms of truncal obesity, small hands with tapered fingers, and small feet. Operation
for strabismus had been performed. When evaluated at 21 years of age, she presented with the major signs of PWS, except for the relatively normal facial
appearance. Wey et al. (2005) suggested that the patient, although presenting with atypical PWS features at birth and in infancy, had progressively
acquired more pronounced PWS features during childhood and adolescence.
Sinnema et al. (2012) reported the clinical features of 12 patients over the age of 50 years with genetically confirmed PWS. Eleven patients lived in a facility,
and 1 lived with his elderly mother. Half of the patients had diabetes mellitus with an average age at diagnosis of 41.6 years. Three patients had
hypertension, 3 had a history of stroke, 6 had a history of fractures, 10 had foot problems, 5 had scoliosis, 9 had edema, and 6 had erysipelas. Older patients
had significantly lower functioning, particularly in activities of daily living, compared to younger control patients, and the decline began around age 40. All
8 patients with maternal uniparental disomy used psychotropic medications, 7 of whom had a psychiatric disorder. None of the 4 patients with a paternal
deletion had a psychiatric illness. Sinnema et al. (2012) suggested that age-associated medical problems may be exacerbated by temperature instability,
decreased mobility, and high pain threshold in PWS. Overall, the constellation of features suggested premature aging in PWS, which may also result from
abnormalities in sex hormone levels. Sinnema et al. (2012) noted that the life expectancy of individuals with PWS had increased in recent years, and that
these individuals have specific medical and social needs as they age.
Prader-Willi-like Syndrome Associated with Chromosome 6
Fryns et al. (1986) described an 8-month-old girl with a de novo 5q/6q autosomal translocation resulting in loss of the distal part of the long arm of
chromosome 6 (6q23.3-qter). Clinical manifestations included abnormal facies with broad, flat nasal bridge, small nose with broad tip, bilateral epicanthus,
narrow palpebral fissures, small anteverted ears, and small mouth. Other features included truncal obesity, short hands and feet, and delayed psychomotor
development. Prader-Willi syndrome was suspected initially.
Villa et al. (1995) reported a 23-month-old boy with mental and psychomotor delay, minor craniofacial abnormalities, and obesity who had a de novo
interstitial deletion of chromosome 6q16.2-q21. The authors noted the phenotypic similarities to Prader-Willi syndrome. In a boy with clinical features
mimicking Prader-Willi syndrome, but with a normal chromosome 15, Stein et al. (1996) found a de novo interstitial deletion of 6q22.2-q23.1. The boy
showed delayed development, hypotonia, seizures, hyperactive behavior, a bicuspid aortic valve with mild aortic stenosis, small hands and feet,
hypogonadism, and obesity since about 4 years of age. In a 38-year-old man with moderate to severe intellectual delay, short stature, small hands and feet,
small mouth, and obesity, Smith et al. (1999) found a duplication of 6q24.3-q27. The authors noted that the phenotype showed similarities to Prader-Willi
syndrome.
As reviewed by Gilhuis et al. (2000), several obese patients with cytogenetic alterations in the same region of 6q had been reported; all had in common some
clinical features, including obesity, hypotonia, and developmental delays, resembling Prader-Willi syndrome. However, their behavior, facial features, and
additional neurologic abnormalities, as well as a lack of cytogenetic changes or imprinting mutations on chromosome 15, clearly distinguished this PWS-
like phenotype from PWS patients.
Holder et al. (2000) studied a girl with early-onset obesity and a balanced translocation between 1p22.1 and 6q16.2. At 67 months of age she weighed 47.5
kg (+9.3 SD) and was 127.2 cm tall (+3.2 SD); her weight for height was +6.3 SD. The child displayed an aggressive, voracious appetite, and the obesity was
thought to be due to high intake, since measured energy expenditure was normal. However, the authors noted that apart from her obesity, there were no
features suggestive of PWS. Genetic analysis of the region on chromosome 6 showed that the translocation disrupted the SIM1 gene (603128). Holder et al.
(2000) hypothesized that haploinsufficiency of the SIM1 gene may be responsible for the obesity. In a boy with a Prader-Willi-like phenotype, Faivre et al.
(2002) identified a deletion of chromosome 6q16.1-q21. Intrauterine growth retardation, oligohydramnios, and a left clubfoot were noted during the third
trimester of pregnancy. Later, generalized obesity, slightly dysmorphic facial features, small hands and feet, clumsiness, and mental retardation were
observed. Molecular analysis showed that the deletion was paternal in origin and resulted in a deletion of the SIM1 gene.
Other Features
Miller et al. (2007) evaluated 3-dimensional brain MRI scans of 20 individuals with PWS aged 3 months to 39 years. Intracranial morphologic abnormalities
included ventriculomegaly (100%), decreased volume of the parietal-occipital lobe (50%), sylvian fissure polymicrogyria (60%), and incomplete insular
closure (65%).
Fan et al. (2009) found that 10 of 56 PWS patients had seizures, 9 of whom had generalized seizures attributable to PWS. The remaining patient was born
with intraventricular hemorrhage and had focal epileptic discharges, which was thought to be responsible for the seizures. Eight of the 9 with PWS-related
seizures had a 15q11-q13 deletion, suggesting that decreased inhibitory effects of the GABA receptor cluster in this region may play a role in
epileptogenesis. Six additional patients of the 56 had paroxysmal events such as staring spells, tremor spells, and collapsing spells.
Inheritance
Familial inheritance of PWS has been described frequently. Gabilan (1962) reported a family with affected brother and sister, as well as a second in which
the parents of the proband were first cousins, but his patients were not entirely typical.
Jancar (1971) reported familial incidence. Hall and Smith (1972) reported 2 affected male maternal first cousins. One was of normal stature and intelligence.
DeFraites et al. (1975) observed 5 cases in 3 sibships of an inbred Louisiana Acadian kindred. Clarren and Smith (1977) reported affected sibs and affected
first cousins. They found a recurrence risk of 1.6% in sibs of probands.
It is clear that chromosomal mechanisms are principally responsible for PWS and that the syndrome is caused by lack of the paternal segment 15q11.2-q12.
Basically, there are 2 mechanisms by which such a loss can occur: either through deletion of just the paternal 'critical' segment or through loss of the entire
paternal chromosome 15 with presence of 2 maternal homologs (uniparental maternal disomy). The opposite, i.e., maternal deletion or paternal uniparental
disomy, causes another characteristic phenotype, the Angelman syndrome (AS; 105830). This indicates that both parental chromosomes are differentially
imprinted, and that both are necessary for normal embryonic development.
Ming et al. (2000) described 2 cousins with Prader-Willi syndrome resulting from a submicroscopic deletion detected by fluorescence in situ hybridization.
Although the karyotype was cytogenetically normal, FISH analysis showed a submicroscopic deletion of SNRPN (182279), but not the closely associated
loci D15S10, D15S11, D15S63, and GABRB3 (137192). The affected female and male were offspring of brothers who carried the deletion but were clinically
normal, as were also 2 paternal aunts of the probands who likewise had the deletion. The grandmother was deceased and not available for study; the
grandfather did not show deletion of SNRPN. DNA methylation analysis of D15S63 was consistent with an abnormality of the imprinting center associated
with PWS. Ming et al. (2000) referred to this as grandmatrilineal inheritance, which occurs when a woman with deletion of an imprinted, paternally
expressed gene is at risk of having affected grandchildren through her sons. In such an instance, PWS does not become evident as long as the deletion is
passed through the female line.
Occurrence of the Prader-Willi Syndrome
The vast majority of PWS cases occur sporadically. These instances include virtually all interstitial deletions, the large majority of de novo unbalanced
translocations, all instances of maternal uniparental disomy with normal karyotype or with a de novo rearrangement involving chromosome 15, and almost
all cases of maternal uniparental disomy with a familial rearrangement involving chromosome 15. There is no parental age effect whatsoever in the deletion
cases.
For full discussion on the mode of inheritance, see Cytogenetics, below.
Recurrence Risk
Monozygotic twins are concordantly affected. However, affected sibs and cousins have repeatedly been reported, and even if a publication bias is
considered, their incidence is obviously higher than the estimated incidence in the population of about 1 in 25,000 would suggest. Clarren and Smith (1977)
reported affected sibs and first cousins. They found a recurrence risk of 1.6% in sibs of probands. Cassidy (1987) stated that the Prader-Willi Syndrome
Association maintained a registry of PWS individuals which, as of December 1986, contained 1,595 names of affected persons in the United States and
Canada. While in some of these cases the diagnosis had not been fully confirmed, in only 1 family, that reported by Lubinsky et al. (1987), was there a well-
documented recurrence. Thus, it is reasonable to assume that the recurrence risk for PWS is less than 1 in 1,000 and that such recurrence is not likely to
occur when a 15q interstitial deletion is identified in the proband. (As pointed out by Kennerknecht (1992), the membership of the PWS association is not
limited to affected persons; 'two thirds are families and one third professionals'.)
Ledbetter et al. (1987) summarized a scientific conference on PWS. Of 195 cases studied by high resolution cytogenetic methods, deletion of chromosome
15 was detected in 116 (59.5%); other chromosome 15 abnormalities were found in 7 additional cases (3.6%). It was suggested that the recurrence risk may
be as low as 1 in 1,000.
Kennerknecht (1992) used the diagnostic criteria given by Cassidy (1987) to evaluate reported cases of PWS with a view to estimating recurrence risk. Since
a deletion at 15q has not been found in familial cases of PWS, except in those where del(15q) is due to familial structural chromosome rearrangement, the
recurrence risk with de novo deletion should be nearly zero. In cases with familial translocation, risk estimates depend on the nature of the translocations
concerned. If only 1 child is affected and the karyotype is apparently normal, Kennerknecht (1992) estimated an overall recurrence risk of 0.4%. However, if
2 or more sibs are affected, he estimated that the risk to the next sib would be 50%. If every proband were investigated cytogenetically (to ascertain
unbalanced chromosome rearrangements), molecularly (with probes to detect invisible deletions and to determine the methylation pattern), and if in each
instance of a paternal deletion an examination of the father was carried out, then the few instances with a high recurrence risk could be ascertained before a
second child was born.
Mutagenic Factors
Strakowski and Butler (1987) found an increased incidence of paternal periconceptional employment in hydrocarbon-exposing occupations. Among 81
patients with PWS, Cassidy et al. (1989) compared the frequency of possible periconceptional occupational hydrocarbon exposure in those fathers who
demonstrated a 15q deletion with the frequency in those who did not. There was no statistically significant difference between the cytogenetically different
groups. In both groups, approximately half the fathers had been employed in hydrocarbon-exposing jobs. The data provided additional support for the
possibility that hydrocarbon exposure is causally related to the disorder and further suggested lack of etiologic heterogeneity between the cytogenetically
different groups.
Cytogenetics
Deletions account for 70 to 80% of cases; the majority are interstitial deletions, many of which can be visualized by prometaphase banding examination. A
minority consist of unbalanced translocations, mostly de novo, which are easily detected by routine chromosome examination. The remainder of cases are
the result of maternal uniparental disomy. In most of these latter cases, cytogenetic examinations yield normal results. However, in a few cases, either
balanced translocations, familial or de novo, or supernumerary small marker chromosomes, are observed.
Deletions
Butler et al. (1986) found an interstitial deletion of chromosome 15 (breakpoints q11 and q13) in 21 of 39 cases and an apparently normal karyotype in the
remainder. By studying chromosome 15 heteromorphisms, the del(15q) was demonstrably paternal in origin in all cases, although both parents were
normal and all deletions were de novo events. Paternal age was not increased. The exclusively paternal origin of deletions was subsequently confirmed
cytogenetically and by molecular marker analysis (Magenis et al., 1990; Zori et al., 1990; Robinson et al., 1991). Examination of other series of patients by
different groups resulted in the figures that two-thirds to three-fourths of PWS patients have a deletion of 15q11-q13. In less than 10%, this is due to an
unbalanced translocation while the remainder have interstitial deletions.
To analyze the mechanism underlying the interstitial de novo deletions at 15q11-q13 that underlie approximately 70% of PWS cases, Carrozzo et al. (1997)
genotyped 10 3-generation families of PWS-deletion patients using microsatellite markers flanking the common deletion region. By FISH and/or other
molecular techniques, each patient was known to be deleted for the interval from D15S11 to GABRB3. In 5 of 7 cases, a different grandparental origin was
identified for the alleles flanking the deletion, a finding significantly different from the expected frequency in light of the close position of the markers. This
finding was considered highly suggestive of an unequal crossover occurring in the paternal meiosis at the breakpoint as the mechanism leading to deletion.
The authors noted that asymmetric exchanges between nonsister chromatids in meiosis I have previously been demonstrated and are the basis of a number
of genetic diseases. When the related sequences are part of tandemly arrayed homologous genes, nonhomologous recombination may lead to the formation
of chimeric genes, such as those of Lapore hemoglobin and of the red-green pigment genes involved in abnormalities of color vision. In other instances, the
deletion/duplication event may arise from the unequal recombination between repetitive elements interspersed throughout a genomic region. A
misalignment between Alu-repetitive sequences has been demonstrated in duplications of the LDL-receptor gene (606945; Lehrman et al., 1987) and the
HPRT gene (308000; Marcus et al., 1993).
In 2 PWS families studied by Carrozzo et al. (1997), the data were consistent with an intrachromosomal mechanism being responsible for the deletion. One
of the few precedents for intrachromosomal recombination leading to human disease is provided by the recombination that occurs between the small
intronless gene within intron 22 of the factor VIII gene (300841), and a copy of gene A (FSA; 305423) located 500 kb telomeric to the F8 gene, a
recombination that causes severe hemophilia (306700) (Lakich et al., 1993). This rearrangement arises almost exclusively in male meioses, indicating that it
is intrachromosomal. Carrozzo et al. (1997) suggested that the in-cis mechanism leading to the deletions in PWS patients may be related either to an
exchange of chromosomal material between sister chromatids or to the formation of an intrachromosomal loop, either during meiosis or as a somatic event,
followed by an excision of the chromosomal material lying between the recombining regions.
Deletions in PWS and AS are subdivided into 2 main groups based on their proximal breakpoints: type 1 deletions encompass the region between BP1 and
BP3 (about 6 Mb) and type 2 deletions encompass the region from BP2 to BP3 (about 5.3 Mb). However, some patients have atypical deletions. Using
methylation-specific multiplex ligation-dependent probe amplification to analyze the type of deletion in 88 PWS patients, Kim et al. (2012) found that 32
(36.4%) had a type 1 deletion and 49 (55.7%) had a type 2 deletion. Seven patients (8%) had atypical larger (2) or smaller (5) de novo deletions that were
associated with unique phenotypic features, although there were no unifying characteristics across the group. Variable atypical clinical features in these
patients included macrocephaly, microcephaly, large hands, no hypopigmentation, lack of facial gestalt, and variable cognitive impairment. Kim et al.
(2012) discussed the possible role of different genes in the manifestation of different features.
Maternal Uniparental Disomy
Nicholls et al. (1989), studying cases of PWS in which no deletion was cytologically evident using RFLP analysis, were the first to demonstrate maternal
uniparental disomy (UPD) in 2 families. Two different, apparently intact, maternal chromosomes were present ('heterodisomy'), and, as with deletion cases
of PWS, there was an absence of paternal genes from the 15q11-q13 segment. Robinson et al. (1991) used cytogenetic and molecular techniques to examine
37 patients with features of PWS. Clinical features in 28 of the patients were thought to fulfill diagnostic criteria for typical PWS. In 21 of these, a deletion of
the 15q11.2-q12 region could be identified molecularly, including several cases in which the cytogenetic results were inconclusive. Five cases of maternal
heterodisomy and 2 of isodisomy for 15q11-q13 were observed. All 9 patients who did not fulfill clinical criteria for typical PWS showed normal maternal
and paternal inheritance of chromosome 15 markers; however, one of these carried a ring-15 chromosome. Thus, all typical PWS cases showed either a
deletion or maternal uniparental disomy of 15q11.2-q12. As the disomy patients did not show any additional or more severe features than did the typical
deletion patients, it is likely that there is only one imprinted region on chromosome 15. A significantly increased mean maternal age was found in the
disomy cases, suggesting an association between increased maternal age and nondisjunction.
Mascari et al. (1992) demonstrated maternal uniparental disomy for chromosome 15 in 18 of 30 patients (60%) without a cytogenetic deletion. Furthermore,
they confirmed the observation of Robinson et al. (1991) that the phenomenon was associated with advanced maternal age. In another 8 patients (27%),
they identified large molecular deletions. The remaining 4 patients (13%) had evidence of normal biparental inheritance for chromosome 15; 3 of these
patients were the only ones in the study which had some atypical clinical features. All told, they estimated that about 20% of cases of PWS result from
maternal uniparental disomy and that, by the combined use of cytogenetic and molecular techniques, the genetic basis of PWS can be identified in at least
95% of patients.
Mitchell et al. (1996) compared 79 cases of PWS with UPD and 43 cases with deletions. Although there were no major clinical differences between the 2
classes of patients analyzed as a whole, mean maternal and paternal age were significantly higher in the UPD patients. The UPD group had a
predominance of males, yet a gender bias was not seen in the deletion group. Hypopigmentation was found in 77% of the deletion group compared to only
39% of the UPD children. When the groups were analyzed by gender, females with UPD tended to be less severely affected than female deletion patients.
Mutirangura et al. (1993) demonstrated maternal heterodisomy in 10 PWS patients. Since the markers used were 13 cM from the centromere,
heterodisomy indicated that maternal meiosis I nondisjunction was primarily involved in the origin of UPD. In contrast, 2 paternal disomy cases of
Angelman syndrome (AS) showed isodisomy for all markers tested along the length of chromosome 15. This suggested a paternal meiosis II nondisjunction
event (without crossing over) or, more likely, monosomic conception (due to maternal nondisjunction) followed by chromosome duplication. The latter
mechanism would indicate that at least some instances of uniparental disomy in PWS and AS initiate as reciprocal products of maternal nondisjunction
events.
Robinson et al. (1993) reported data indicating that the majority (82%) of maternal nondisjunction events leading to UPD and causing PWS involve a
meiosis I error, whereas most paternal UPD Angelman syndrome cases are meiosis II or, more likely, mitotic errors. Robinson et al. (1993) made the
interesting statement that the proportion of UPD cases among all PWS patients in Switzerland is higher than in the United States, which could reflect the
higher mean maternal age at birth in Switzerland versus the United States.
Gold et al. (2014) studied the frequency of Prader-Willi syndrome in births conceived via assisted reproductive technology (ART). The overall incidence in
those who used ART was 1.1%; the population frequency for the United States was 1.0%. However, the proportion of individuals with maternal disomy
15/imprinting defects born after ART was higher than that in the total sample, 55.6% (10 of 18) and 34.5% (431 of 1,250), respectively. As compared with
naturally conceived individuals with Prader-Willi syndrome, those who were ART-conceived were more likely to have uniparental disomy and imprinting
defects than deletions. This study also demonstrated no association between twinning and Prader-Willi syndrome when ART-conceived pregnancies were
excluded.
Rescuing of Trisomy 15
Maternal nondisjunction does not itself directly lead to uniparental disomy but must also involve a further nondisjunction event to produce a euploid
embryo. Purvis-Smith et al. (1992) have confirmed such an origin of uniparental disomy 15 resulting from 'correction' of an initial trisomy 15. Routine
chorionic villus sampling performed for advanced maternal age led to detection of placental mosaicism for trisomy 15. Follow-up studies on amniotic fluid
indicated a normal 46,XY karyotype with no evidence of trisomy 15, and the pregnancy continued to term. At birth, the baby was found to have PWS.
Molecular analysis indicated that the mother was the sole contributor of the chromosome 15 pair in the child. Centromere/short-arm heteromorphisms were
different in the 2 chromosome 15 homologs, consistent with meiosis I error. Cassidy et al. (1992) reported a similar case that supported the idea that
maternal disomy can result from a 'corrected' trisomy 15 and that maternal age was a predisposing factor to nondisjunction. Thus, in any case in which
trisomy or mosaic trisomy 15 has been prenatally determined through CVS examination, a molecular study should follow to exclude uniparental (paternal
or) maternal disomy. This type of examination should also be considered in case of pregnancies of translocation carrier parents involving chromosome 15.
Devriendt et al. (1997) proposed partial zygotic trisomy rescue as a mechanism for mosaicism for a de novo jumping translocation of distal chromosome
15q, resulting in partial trisomy for 15q24-qter in a patient with PWS. A maternal uniparental heterodisomy for chromosome 15 was present in all cells and
was responsible for the PWS phenotype. The translocated 15q segment was of paternal origin and was present as a jumping translocation, involving
chromosomes 14q, 4q, and 16p. The recipient chromosomes were cytogenetically intact. Devriendt et al. (1997) reported that mental retardation was more
marked in their patient than is usually observed in PWS, and proposed that this was due to partial trisomy for distal 15q.
Multiple Affected Relatives
There are several mechanisms that explain the simultaneous occurrence of affected first- and second-degree relatives in PWS families. These include
translocations that give rise to maternal nondisjunction and hence effective maternal uniparental disomy for the PWS region and translocations which give
rise to paternally derived deletions.
The first report of involvement of a D group translocation in PWS (later identified as a 15-15 translocation) dates back to 1963 (Buehler et al., 1963).
Additional translocations were found subsequently, and after the introduction of chromosome banding it became obvious that at least one chromosome 15
was involved in all instances (Zuffardi et al., 1978; Kucerova et al., 1979; Guanti, 1980). However, the situation was further complicated by cases in which
not only the proband had a translocation involving chromosome 15, but the mother and 2 normal sibs showed the seemingly identical translocation as well
(Smith and Noel, 1980). In addition, there were a few cases that did not show a translocation involving chromosome 15, but had a small supernumerary
chromosome, presumably an isochromosome for the short arm of an acrocentric (Fleischer-Michaelsen et al., 1979; Fujita et al., 1980; Wisniewski et al.,
1980).
Smith and Noel (1980) described a family in which a Prader-Willi girl had the same balanced 4;15 translocation as her mother and other phenotypically
normal family members. A second such family was observed by Smith et al. (1983). Nicholls et al. (1989) reported a similar family and demonstrated that
the Prader-Willi proband had inherited the maternal translocation chromosome plus the normal maternal homolog, but no paternal 15. Therefore, having a
balanced translocation involving chromosome 15 predisposes to PWS offspring via nondisjunction, and this is a much more frequent cause than
spontaneous nondisjunction, which may arise from chromosomally normal individuals. The opposite, i.e., Angelman syndrome, could also occur with
paternal translocation carriers.
The simplest instance is that of a balanced rearrangement with a breakpoint in 15q13 in related male carriers. Fernandez et al. (1987) reported a family with
a 15;22 translocation carrier father who had 2 children with PWS because of an unbalanced segregation. Hulten et al. (1991) described a family in which a
balanced translocation involving 15q13 was segregating. Females with the translocation appeared to have an increased risk of having children with AS,
whereas male carriers of the translocation had an increased risk of having children with PWS.
Ledbetter et al. (1980) pointed out that apparent balanced translocations involving chromosome 15 have been found. The defect may be an alteration in
gene expression, i.e., a regulatory defect. Ledbetter et al. (1981), assuming a small deletion of proximal 15q as the cause of the clinical features in the
translocated cases, studied 45 persons with the clinical diagnosis of PWS. Of the 45, 25 had an abnormality of chromosome 15 (which in 23 was an
interstitial deletion affecting the q11-q12 region). No relatives of probands showed chromosomal changes.
Orstavik et al. (1992) described 3 sibs thought to have the Prader-Willi syndrome but with no abnormality in the 15q11-q13 region detectable by
cytogenetic or molecular genetic methods. One of the sibs, a boy, was born at 32 weeks by cesarean section. He was extremely hypotonic and died at 7
days of age from respiratory distress. The other sibs, a 12-year-old brother and a 7-year-old sister, had an accessory nipple and seemingly typical PWS. A
paternally inherited submicroscopic deletion was suggested as one possibility. A very small deletion was later molecularly detected in affected members of
this family (Tommerup, 1993).
Ishikawa et al. (1987) described 2 sisters with PWS. No interstitial deletion of 15q was detected in either; 1 sister had a possibly unrelated partial deletion of
one X chromosome. No molecular investigations were performed in this family.
Lubinsky et al. (1987) reported the cases of 2 brothers and 2 sisters in a single sibship with PWS but apparently normal chromosomes. Results of
chromosome studies in the parents and surviving sibs were normal. The diagnosis was made clinically on the basis of history, behavior, and physical
findings in 3 of the sibs. The fourth child had died at the age of 10 months with a history and clinical findings typical of the first phase of PWS. Again, no
molecular or fluorescence in situ hybridization (FISH) studies were performed. It seems likely that an undetected structural chromosome rearrangement is
the cause for this multiple occurrence of PWS.
McEntagart et al. (2000) described a brother and sister with PWS in whom there was no microscopically visible deletion in 15q11-q13 or maternal disomy.
Methylation studies at D15S63 and at the SNRPN locus confirmed the diagnosis of PWS. Molecular studies revealed biparental inheritance in both sibs
with the exception of 2 markers where no paternal contribution was present, indicating a deletion of the imprinting center. Family studies indicated that the
father of the sibs carried the deletion which he had inherited from his mother. Recurrence risk of PWS in his offspring was 50%.
Co-Occurrence of Prader-Willi and Angelman Syndromes
Hasegawa et al. (1984) studied a family in which 2 cousins were claimed to have the Prader-Willi syndrome and found a reciprocal translocation t(14;15)
(q11.2;q13) in a single parent of each cousin and in their common grandmother. The affected cousins had the same unbalanced translocation including
monosomy of the 15pter-q13 segment. Schinzel et al. (1992) pointed out that the unbalanced karyotype with deletion of 15q11-q13 came from the mother
in the case of the proband who had been described to have classic Prader-Willi syndrome and from the father in the case of the cousin; the mother of the
proband and the father of the cousin were sister and brother. However, the proband was not hypotonic and had seizures. Schinzel et al. (1992) suggested
that the diagnosis in the proband actually may have been Angelman syndrome, consistent with the finding that there has been no reported instance of a
patient in which absence of the paternal segment 15q11-q13 does not cause PWS, while the absence of the maternal segment leads to AS.
Another mechanism by which the Prader-Willi syndrome and Angelman syndrome can occur in cousins was reported by Smeets et al. (1992). Two female
first cousins were offspring of brothers, both of whom had a familial translocation between chromosome 6 and 15, t(6;15)(p25.3;q11.1). The cousin with the
Prader-Willi syndrome had the karyotype 45,XX,-6,-15+t(6;15)(p25.3;q13); DNA studies indicated that there was a large paternally derived deletion of all
loci from the Prader-Willi chromosomal region tested. The cousin with Angelman syndrome had the karyotype 45,XX,-6,-15,+t(6;15)(p25.3;q11.1) and DNA
studies indicated that she had uniparental heterodisomy, having inherited both the (6;15) translocation and the normal chromosome 15 from her father, but
no chromosome 15 from her mother. In an editorial, Hall (1992) suggested that the cousin with Angelman syndrome had started out life as a trisomy and
survived only through the loss of extra chromosomal material.
Greenstein (1990) presented a kindred in which both the Prader-Willi and the Angelman syndromes were found; the inheritance pattern was consistent with
genetic imprinting.
Marker Chromosomes
Finally, additional small marker chromosomes representing isochromosomes or isodicentric chromosomes from the short arms of acrocentrics have
repeatedly been observed (Fleischer-Michaelsen et al., 1979; Fujita et al., 1980; Wisniewski et al., 1980) before Robinson et al. (1993) demonstrated maternal
uniparental disomy 15 in a Prader-Willi child mosaic for such a marker and paternal UPD 15 in an Angelman patient also mosaic for a small metacentric
marker chromosome.
Investigation of PWS and AS patients with a small inv dup(15) chromosome attributes the abnormal phenotype to uniparental disomy rather than to the
extra chromosome (Robinson et al., 1993). The small chromosome may represent either the remnant of the missing parental chromosome 15 or could be
associated with nondisjunction.
Park et al. (1998) described an example of maternal disomy and Prader-Willi syndrome consistent with gamete complementation. They considered that the
probable event was adjacent-1 segregation of a paternal t(3;15)(p25;q11.2) with simultaneous maternal meiotic nondisjunction for chromosome 15. The
patient, a 17-year-old white male with PWS, had 47 chromosomes with a supernumerary, paternal der(15) consisting of the short arm and the proximal
long arm of chromosome 15 fused to distal 3p. The t(3;15) was present in the balanced state in the patient's father and a sister. Fluorescence in situ
hybridization analysis demonstrated that the PWS critical region resided on the derivative chromosome 3 and that there was no deletion in the PWS region
on the normal pair of 15s present in the patient. Maternal disomy was confirmed by 2 methods.
Mapping
Kirkilionis et al. (1991) constructed a long-range restriction map of the PWS region, 15q11.1-q12, using a combination of pulsed-field gel techniques and
rare cutting restriction enzymes.
A preliminary YAC contig map was reported by Kuwano et al. (1992), which also localized many common proximal and distal deletion breakpoints to two
YACs. Ozcelik et al. (1992) refined the localization of the small nuclear ribonucleoprotein N gene (SNRPN; 182279) within the minimum deletion region.
FISH ordering of reference markers in this region was also reported by Knoll et al. (1993) who placed D15S63 in the minimum PWS deletion region
between D15S13 and D15S10. Mutirangura et al. (1993) published a complete YAC contig of the PWS/AS critical region and discussed the potential role of
uniparental disomy (UPD) in PWS and AS. Buiting et al. (1993) constructed a YAC restriction map of the entire minimum PWS critical region defined by
the shortest region of overlap between two key PWS deletion patients. This region is 320 kb and includes D15S63 and SNRPN.
Molecular Genetics
Latt et al. (1987) isolated probes from the proximal region of the long arm of chromosome 15 that are useful in the study of PWS.
Buiting et al. (1992) isolated a putative gene family and candidate genes by microdissection and microcloning from the 15q11-q13 region. One microclone,
designated MN7, detected multiple loci in 15q11-q13 and 16p11.2. There were 4 or 5 different MN7 copies spread over a large distance within 15q11-q13.
The presence of multiple copies of the MN7 gene family in proximal 15q may be related to the instability of this region and thus to the etiology of PWS and
Angelman syndrome.
Using restriction digests with the methyl-sensitive enzymes HpaII and HhaI and probing Southern blots with several genomic and cDNA probes, Driscoll et
al. (1992) systematically scanned segments of 15q11-q13 for DNA methylation differences between patients with PWS (20 deletion cases and 20 cases of
uniparental disomy) and those with AS (26 deletion cases and 1 case of uniparental disomy). They found that the sequences identified by the cDNA DN34,
which is highly conserved in evolution, demonstrate distinct differences in DNA methylation of the parental alleles at the D15S9 locus. Clayton-Smith et al.
(1993) used DN34 to perform methylation analysis of 2 first-cousin males, one with AS and the other with PWS. The methylation pattern varied according
to the parent of origin, providing further evidence for the association of methylation with genomic imprinting. Thus, DNA methylation can be used as a
reliable postnatal diagnostic tool. Dittrich et al. (1992) found that an MspI/HpaII restriction site at the D15S63 locus in 15q11-q13 is methylated on the
maternally derived chromosome, but unmethylated on the paternally derived chromosome. Based on this difference, they devised a rapid diagnostic test for
patients suspected of having PWS or AS.
The human homolog for the mouse pink-eyed dilution locus (p locus) was found to be equivalent to the D15S12 locus which maps within the PWS/AS
deletion region (Rinchik et al., 1993). Mutations in both copies of the P gene were found in a patient with type II oculocutaneous albinism, and it is
suggested that deletion of 1 copy of this gene is the cause of hypopigmentation in PWS and AS.
The SNRPN gene was shown by RT-PCR to be expressed in normal and AS individuals, but not in fibroblasts from either deletion or maternal UPD PWS
patients who lack a paternal copy of this gene (Glenn et al., 1993). Parent-specific DNA methylation was also identified for the SNRPN gene. Reed and Leff
(1994) showed that in the human, as in the mouse, there is maternal imprinting of SNRPN, thus supporting the hypothesis that paternal absence of
SNRPN is responsible for the PWS phenotype. See SNRPN (182279) for discussion of evidence indicating that this is a candidate gene in PWS and
suggesting that PWS may be caused, in part, by defects in mRNA processing. In 2 sibs with the typical phenotype of PWS but without a cytogenetically
detectable deletion in 15q, Ishikawa et al. (1996) demonstrated deletion of SNRPN by FISH.
A DNA transcript, OP2, was identified just centromeric to D15S10 by Woodage et al. (1994). Multiple expressed genes were identified by Sutcliffe (1994) in
the region between SNRPN and D15S10. They showed that at least 4 genes are expressed only on the paternal chromosome including SNRPN, PAR1
(600161), PAR5 (600162), and PAR7. A PWS patient with a small paternal deletion showed no expression of these genes, even though the deletion occurs
proximal to but not including these maternally imprinted genes, implying a common element involved in regulation of these genes. Wevrick et al. (1994)
identified another expressed gene in the region, designated IPW (601491) for 'imprinted gene in the Prader-Willi syndrome region,' that is expressed only
from the paternal chromosome 15.
DNA replication was shown by FISH to be asynchronous between maternal and paternal alleles within 15q11-q13 (Knoll et al., 1993). Loci in the PWS-
critical region were shown to be early replicating on the paternal chromosome, and alleles within the AS critical region were early replicating on the
maternal chromosome. A mosaic replication pattern with maternal and paternal alleles alternatively expressed was noted at the P locus, and is consistent
with the presence of hypopigmentation in both PWS and AS due to decreased product.
Schulze et al. (1996) reported a boy with PWS who had a rare translocation and a normal methylation pattern at SNRPN. Although the boy fulfilled the
diagnostic criteria for PWS defined by Holm et al. (1993), he had a normal methylation pattern due to the position of the translocation breakpoint.
Cassidy (1997) provided a comprehensive review of the clinical and molecular aspects of Prader-Willi syndrome. Cassidy and Schwartz (1998) provided a
similar review of both Prader-Willi syndrome and Angelman syndrome.
PWS and AS are caused by the loss of function of imprinted genes in proximal 15q. In approximately 2 to 4% of patients, this loss of function is the result of
an imprinting defect. In some cases, the imprinting defect is the result of a parental imprint-switch failure caused by a microdeletion of the imprinting
center (IC). Buiting et al. (1998) described the molecular analysis of 13 PWS patients and 17 AS patients who had an imprinting defect but no IC deletion.
Furthermore, heteroduplex and partial sequence analyses did not reveal any point mutations in the known IC elements. All of these patients represented
sporadic cases, and some shared the paternal PWS or maternal AS 15q11-q13 haplotype with an unaffected sib. In each of the 5 PWS patients informative
for the grandparental origin of the incorrectly imprinted chromosome region and 4 cases described elsewhere, the maternally imprinted paternal
chromosome region was inherited from the paternal grandmother. This suggested that the grandmaternal imprint was not erased in the father's germline.
In 7 informative AS patients reported by Buiting et al. (1998) and in 3 previously reported patients, the paternally imprinted maternal chromosome region
was inherited from either the maternal grandfather or the maternal grandmother. The latter finding was not compatible with an imprint-switch failure, but
it suggested that a paternal imprint developed either in the maternal germline or postzygotically. Buiting et al. (1998) concluded that (1) the incorrect
imprint in non-IC-deletion cases is the result of a spontaneous prezygotic or postzygotic error; (2) these cases have a low recurrence risk; and (3) the paternal
imprint may be the default imprint.
Buiting et al. (2003) described a molecular analysis of 51 patients with PWS and 85 patients with AS. A deletion of an IC was found in 7 patients with PWS
(14%) and 8 patients with AS (9%). Sequence analysis of 32 PWS patients and 66 AS patients, neither with an IC deletion, did not reveal any point mutation
in the critical IC elements. The presence of a faint methylated band in 27% of patients with AS and no IC deletion suggested that these patients were mosaic
for an imprinting defect that occurred after fertilization. In patients with AS, the imprinting defect occurred on the chromosome that was inherited from
either the maternal grandfather or grandmother; however, in all informative patients with PWS and no IC deletion, the imprinting defect occurred on the
chromosome inherited from the paternal grandmother. These data suggested that this imprinting defect resulted from a failure to erase the maternal
imprint during spermatogenesis.
Microdeletions of the imprinting center in 15q11-q13 have been identified in several families with PWS or Angelman syndrome who show epigenetic
inheritance for this region that is consistent with a mutation in the imprinting process. The IC controls resetting of parental imprints in this region of 15q
during gametogenesis. Ohta et al. (1999) identified a large series of cases of familial PWS, including 1 case with a deletion of only 7.5 kb, that narrowed the
PWS critical region to less than 4.3 kb spanning the SNRPN gene CpG island and exon 1. The identification of a strong DNase I hypersensitive site, specific
for the paternal allele, and 6 evolutionarily conserved (human-mouse) sequences that are potential transcription factor binding sites is consistent with a
conclusion that this region defines the SNRPN gene promoter. These findings suggested that promoter elements at SNRPN play a key role in the initiation
of imprint switching during spermatogenesis. Ohta et al. (1999) also identified 3 patients with sporadic PWS who had an imprinting mutation (IM) and no
known detectable mutation in the IC. An inherited 15q11-q13 mutation or a trans-factor gene mutation are unlikely; thus, the disease in these patients may
arise from a developmental or stochastic failure to switch the maternal-to-paternal imprint during parental gametogenesis. These studies allowed a better
understanding of the novel mechanism of human disease, since the epigenetic effect of an imprinting mutation in parental germline determines the
phenotypic effect in the patient.
To elucidate the mechanism underlying the deletions that lead to PWS and Angelman syndrome, Amos-Landgraf et al. (1999) characterized the regions
containing 2 proximal breakpoint clusters and a distal cluster. Analysis of rodent-human somatic cell hybrids, YAC contigs, and FISH of normal or
rearranged chromosomes 15 identified duplicated sequences, termed 'END' repeats, at or near the breakpoints. END-repeat units are derived from large
genomic duplications of the HERC2 gene (605837) (Ji et al., 1999). Many copies of the HERC2 gene are transcriptionally active in germline tissues. Amos-
Landgraf et al. (1999) postulated that the END repeats flanking 15q11-q13 mediate homologous recombination resulting in deletion. Furthermore, they
proposed that active transcription of these repeats in male and female germ cells may facilitate the homologous recombination process.
To identify additional imprinted genes that could contribute to the PWS phenotype and to understand the regional control of imprinting in 15q11-q13, Lee
and Wevrick (2000) constructed an imprinted transcript map of the PWS-AS deletion interval. They found 7 new paternally expressed transcripts localized
to a domain of approximately 1.5 Mb surrounding the SNRPN-associated imprinting center, which already included 4 imprinted, paternally expressed
genes. All other tested new transcripts in the deletion region were expressed from both alleles. A domain of exclusive paternal expression surrounding the
imprinting center suggested strong regional control of the imprinting process. Bielinska et al. (2000) reported a PWS family in which the father was mosaic
for an imprinting center deletion on his paternal chromosome. The deletion chromosome had acquired a maternal methylation imprint in his somatic cells.
Identical observations were made in chimeric mice generated from 2 independent embryonic stem cell lines harboring a similar deletion. Bielinska et al.
(2000) concluded that the Prader-Willi syndrome imprinting center element is not only required for the establishment of the paternal imprint, but also for
its postzygotic maintenance.
Boccaccio et al. (1999) and Lee et al. (2000) independently cloned and characterized MAGEL2 (605283), a gene within the PWS deletion region. They
demonstrated that the MAGEL2 gene is transcribed only from the paternal allele.
Balanced translocations affecting the paternal copy of 15q11-q13 have been proven to be a rare cause of PWS or PWS-like features. Wirth et al. (2001)
reported a de novo balanced reciprocal translocation t(X;15)(q28;q12) in a female patient with atypical PWS. The translocation breakpoints in this patient
and 2 previously reported patients mapped 70 to 80 kb distal to the SNURF-SNRPN gene (182279) and defined a breakpoint cluster region. The
breakpoints disrupted one of several previously unknown 3-prime exons of this gene. RT-PCR experiments demonstrated that sequences distal to the
breakpoint, including the C/D box small nucleolar RNA (snoRNA) gene cluster HBII-85/PWCR1 (SNORD116-1; 605436), as well as IPW (601491) and
PAR1 (600161), were not expressed in the patient. The authors suggested that lack of expression of these sequences may contribute to the PWS phenotype.
Meguro et al. (2001) determined the allelic expression profiles of 118 cDNA clones using monochromosomal hybrids retaining either a paternal or maternal
human chromosome 15. There was a preponderance of unusual transcripts lacking protein-coding potential that were expressed exclusively from the
paternal copy of the critical interval. This interval also encompassed a large direct repeat (DR) cluster displaying a potentially active chromatin
conformation of paternal origin, as suggested by enhanced sensitivity to nuclease digestion. Database searches revealed an organization of tandemly
repeated consensus elements, all of which possessed well-defined C/D box sequences characteristic of small nucleolar RNAs (snoRNAs). Southern blot
analysis further demonstrated a considerable degree of phylogenetic conservation of the DR locus in the genomes of all mammalian species tested. The
authors suggested that there may be a potential direct contribution of the DR locus, representing a cluster of multiple snoRNA genes, to certain phenotypic
features of PWS.
Fulmer-Smentek and Francke (2001) explored whether differences in histone acetylation exist between the 2 parental alleles of SNRPN and other paternally
expressed genes in the region by using a chromatin immunoprecipitation assay with antibodies against acetylated histones H3 (see 601058) and H4 (see
602822). SNRPN exon 1, which is methylated on the silent maternal allele, was associated with acetylated histones on the expressed paternal allele only.
SNRPN intron 7, which is methylated on the paternal allele, was not associated with acetylated histones on either allele. The paternally expressed genes
NDN, IPW, PWCR1/HBII-85, and MAGEL2 were not associated with acetylated histones on either allele. Treatment of the lymphoblastoid cells with
trichostatin A, a histone deacetylase inhibitor, did not result in any changes to SNRPN expression or association of acetylated histones with exon 1.
Treatment with 5-aza-deoxycytidine, which inhibits DNA methylation, resulted in activation of SNRPN expression from the maternal allele, but was not
accompanied by acetylation of histones. The authors hypothesized that histone acetylation at this site may be important for regulation of SNRPN and of
other paternally expressed genes in the region, and that histone acetylation may be a secondary event in the process of gene reactivation by CpG
demethylation.
The Prader-Willi syndrome/Angelman syndrome region on chromosome 15q11-q13 exemplifies coordinate control of imprinted gene expression over a
large chromosomal domain. Establishment of the paternal state of the region requires the PWS imprinting center (PWS-IC); establishment of the maternal
state requires the AS-IC. Cytosine methylation of the PWS-IC, which occurs during oogenesis in mice, occurs only after fertilization in humans, so this
modification cannot be the gametic imprint for the PWS/AS region in humans. Xin et al. (2001) demonstrated that the PWS-IC shows parent-specific
complementary patterns of histone H3 (see 602810) lysine-9 (lys9) and H3 lysine-4 (lys4) methylation. H3 lys9 is methylated on the maternal copy of PWS-
IC and H3 lys4 is methylated on the paternal copy. Xin et al. (2001) suggested that H3 lys9 methylation is a candidate maternal gametic imprint for this
region, and they showed how changes in chromatin packaging during the life cycle of mammals provide a means of erasing such an imprint in the male
germline.
Bittel et al. (2003) performed cDNA microarray analysis of 73 genes/transcripts from the 15q11-q13 region in actively growing lymphoblastoid cell lines
established from 9 young adult males: 6 with PWS (3 with deletion and 3 with UPD) and 3 controls. They detected no difference in expression of genes with
known biallelic expression located outside the 15q11-q13 region in all cell lines studied. When comparing UPD cell lines with controls, there was no
difference in expression levels of biallelically expressed genes from within 15q11-q13 (e.g., OCA2; 611409). Two genes previously identified as maternally
expressed, UBE3A (601623) and ATP10C (605855), showed a significant increase in expression in UPD cell lines compared with those from control and
PWS deletion patients. The results suggested that differences in expression of candidate genes may contribute to phenotypic differences between the
deletion and UPD types of PWS.
Horsthemke et al. (2003) described a girl with PWS who was mosaic for maternal uniparental disomy 15 [upd(15)mat] in blood and skin. The upd event
occurred prior to X inactivation. DNA microarray experiments on cloned normal and upd fibroblasts detected several chromosome 15 genes known to be
imprinted, but there was no evidence for novel 15q genes showing imprinted expression. Differentially expressed genes on other chromosomes were
considered candidates for downstream genes regulated by an imprinted gene and may play a role in the pathogenesis of PWS. Upon finding strongly
reduced mRNA levels in upd(15)mat cells of the gene encoding secretogranin II (SCG2; 118930), a precursor of the dopamine-releasing factor secretoneurin,
the authors speculated that the hyperphagia in patients with PWS might be due to a defect in dopamine-modulated food reward circuits.
Kantor et al. (2004) constructed a transgene including both the 4.3-kb SNRPN promoter/exon 1 (PWS-SRO) sequence and the 880-bp sequence (AS-SRO)
located 35 kb upstream of the SNRPN transcription start site and determined that the transgene carried out the entire imprinting process. The epigenetic
features of this transgene resembled those previously observed on the endogenous locus, thus allowing analyses in mouse gametes and early embryos. In
gametes, they identified a differentially methylated CpG cluster (DMR) on AS-SRO that was methylated in sperm and unmethylated in oocytes. This DMR
specifically bound a maternal allele-discrimination protein that was involved in DMR maintenance through implantation when methylation of PWS-SRO
on the maternal allele takes place. While the AS-SRO was required in gametes to confer methylation on PWS-SRO, it was dispensable later in development.
The Prader-Willi deleted region on chromosome 15q11 contains a small nucleolar RNA (snoRNA), HBII-52 (SNORD115-1; 609837), that exhibits sequence
complementarity to the alternatively spliced exon Vb of the serotonin receptor HTR2C (312861). Kishore and Stamm (2006) found that HBII-52 regulates
alternative splicing of HTR2C by binding to a silencing element in exon Vb. Prader-Willi syndrome patients do not express HBII-52. They have different
HTR2C mRNA isoforms than healthy individuals. Kishore and Stamm (2006) concluded that a snoRNA regulates the processing of an mRNA expressed
from a gene located on a different chromosome, and the results indicate that a defect in pre-mRNA processing contributes to the Prader-Willi syndrome.
Runte et al. (2005) found that individuals with complete deletion of all copies of HBII-52 had no obvious clinical phenotype, suggesting that HBII-52 does
not play a major role in PWS.
Sahoo et al. (2008) reported a boy with all of 7 major clinical criteria for Prader-Willi syndrome, including neonatal hypotonia, feeding difficulties and
failure to thrive during infancy, excessive weight gain after 18 months, hyperphagia, hypogonadism, and global developmental delay; facial features were
considered equivocal, with bitemporal narrowing and almond-shaped eyes. Additional minor features included behavioral problems, sleep apnea, skin
picking, speech delay, and small hands and feet relative to height. High-resolution chromosome and array comparative genomic hybridization showed an
atypical deletion of the paternal chromosome within the snoRNA region at chromosome 15q11.2. The deletion encompassed HBII-438A, all 29 snoRNAs
comprising the HBII-85 cluster, and the proximal 23 of the 42 snoRNAs comprising the HBII-52 cluster. The data suggested that paternal deficiency of the
HBII-85 cluster may cause key manifestations of the PWS phenotype, although some atypical features suggested that other genes in the region may make
lesser phenotypic contributions.
De Smith et al. (2009) reported a 19-year-old male with hyperphagia, severe obesity, mild learning difficulties, and hypogonadism, in whom diagnostic
tests for PWS had been negative. The authors identified a 187-kb deletion at chromosome 15q11-q13 that encompassed several exons of SNURF-SNRPN,
the HBII-85 cluster (SNORD116-1; 605436), and IPW but did not include the HBII-52 cluster. HBII-85 snoRNAs were not expressed in peripheral
lymphocytes from the patient. Characterization of the clinical phenotype revealed increased ad libitum food intake, normal basal metabolic rate when
adjusted for fat-free mass, partial hypogonadotropic hypogonadism, and growth failure. These findings provided direct evidence for the role of a particular
family of noncoding RNAs, the HBII-85 snoRNA cluster, in human energy homeostasis, growth, and reproduction.
Using bioinformatic predictions and experimental verification, Kishore et al. (2010) identified 5 pre-mRNAs (DPM2, 603564; TAF1, 313650; RALGPS1,
614444; PBRM1, 606083; and CRHR1, 122561) containing alternative exons that are regulated by MBII-52, the mouse homolog of HBII-52. Analysis of a
single member of the MBII-52 cluster of snoRNAs by RNase protection and Northern blot analysis showed that the MBII-52 expressing unit generated
shorter RNAs that originate from the full-length MBII-52 snoRNA through additional processing steps. These novel RNAs associated with hnRNPs and not
with proteins associated with canonical C/D box snoRNAs. Kishore et al. (2010) concluded that not a traditional C/D box snoRNA MBII-52, but a processed
version lacking the snoRNA stem, is the predominant MBII-52 RNA missing in Prader-Willi syndrome. This processed snoRNA functions in alternative
splice site selection.
Kaminsky et al. (2011) presented the largest copy number variant case-control study to that time, comprising 15,749 International Standards for
Cytogenomic Arrays cases and 10,118 published controls, focusing on recurrent deletions and duplications involving 14 copy number variant regions.
Compared with controls, 14 deletions and 7 duplications were significantly overrepresented in cases, providing a clinical diagnosis as pathogenic. The
15q11.2-q13 (BP2-BP3) deletion was identified in 41 cases and no controls for a p value of 2.77 x 10(-9) and a frequency of 1 in 384 cases.
Diagnosis
Seven clinicians experienced with PWS, in consultation with national and international experts, proposed 2 scoring systems as diagnostic criteria: one for
children aged 0-36 months and another for children aged 3 years to adults (Holm et al., 1993).
The American Society of Human Genetics/American College of Medical Genetics Test and Technology Transfer Committee (1996) outlined approaches to
the laboratory diagnosis of PWS and Angelman syndrome.
White et al. (1996) exploited the allele-specific replication differences that had been observed in imprinted chromosomal regions to obtain a diagnostic test
for detecting uniparental disomy. They used FISH of D15S9 and SNRPN (182279) on interphase nuclei to distinguish between Angelman and Prader-Willi
syndrome patient samples with uniparental disomy of 15q11-q13 and those with biparental inheritance. They found that the familial recurrence risks are
low when the child has de novo uniparental disomy and may be as high as 50% when the child has biparental inheritance. The frequency of interphase cells
with asynchronous replication was significantly lower in patients with uniparental disomy than in patients with biparental inheritance. Within the sample
population of patients with biparental inheritance, those with altered methylation and presumably imprinting center mutations could not be distinguished
from those with no currently detectable mutation. White et al. (1996) considered the test cost-effective because it could be performed on interphase cells
from the same hybridized cytologic preparation in which a deletion was included, and additional specimens were not required to determine the parental
origin of chromosome 15.
Kubota et al. (1996) noted that neither FISH nor uniparental disomy (UPD) analysis with microsatellite markers will detect rare PWS patients with
imprinting mutations, including small deletions or point mutations in the imprinting center region. They reported that as an initial screening test,
methylation analysis has the advantage of detecting all of the major classes of molecular defects involved in PWS (deletions, uniparental disomy, and
imprinting mutations) without the need for parental blood. Kubota et al. (1996) reported that in 67 patients examined clinically, the methylation results for
PW71 were consistent with the clinical diagnosis. They concluded that SNRPN methylation analysis, similar to PW71 methylation analysis, constitutes a
reliable diagnostic test for PWS. They emphasized the importance of conventional cytogenetic analysis in parallel with DNA methylation analysis. They
noted that a few patients with signs of PWS have balanced translocations within or distal to SNRPN and normal methylation patterns. They noted also that
conventional cytogenetic analysis is important to rule out other cytogenetic anomalies in patients who may have similar clinical manifestations but who do
not have PWS.
Since the SNRPN gene is not expressed in any patient with PWS regardless of the underlying cytogenetic or molecular cause, Wevrick and Francke (1996)
tested for expression of the SNRPN gene and a control gene in 9 patients with PWS and 40 control individuals by PCR analysis of reverse transcribed
mRNA from blood leukocytes. SNRPN expression could readily be detected in blood leukocytes by PCR analysis in all control samples but not in samples
from known PWS patients. Four suspected PWS cases were negative for SNRPN expression and were found to have chromosome 15 rearrangements, while
the diagnosis of PWS was excluded in 7 other patients with normal SNRPN expression based on clinical, molecular, and cytogenetic findings. Thus,
Wevrick and Francke (1996) concluded that the SNRPN-expression test is rapid and reliable in the molecular diagnosis of PWS.
The diagnostic criteria arrived at by a consensus group (Holm et al., 1993) were presented in a table by Schulze et al. (1996). In a point system, 1 point each
was allowed for each of 5 major criteria, such as feeding problems in infancy and failure to thrive, and one-half point each for 7 minor criteria, such as
hypopigmentation. A minimum of 8.5 points was considered necessary for the diagnosis of PWS.
Hordijk et al. (1999) reported a boy with a PWS-like phenotype who was found to have maternal heterodisomy for chromosome 14. The authors noted that
while previous reports of this phenotype had been associated with a Robertsonian translocation involving chromosome 14, in this case the karyotype was
normal. Hordijk et al. (1999) concluded that patients with a PWS-like phenotype and normal results of DNA analysis for PWS should be reexamined for
uniparental disomy for maternal chromosome 14.
Whittington et al. (2002) compared clinical and genetic laboratory diagnoses of PWS. The genetic diagnosis was established using the standard
investigation of DNA methylation of SNRPN, supplemented with cytogenetic studies. The 5 clinical features of floppy at birth, weak cry or inactivity, poor
suck, feeding difficulties, and hypogonadism were present in 100% of persons with positive genetic findings, the absence of any 1 predicting a negative
genetic finding. The combination of poor suck at birth, weak cry or inactivity, decreased vomiting, and thick saliva correctly classified 92% of all cases.
Whittington et al. (2002) hypothesized that these criteria ('core criteria') invariably present when genetic findings are positive and are necessary
accompaniments of the genetics of PWS. No subset of clinical and behavioral criteria was sufficient to predict with certainty a positive genetic diagnosis, but
the absence of any 1 of the core criteria predicted a negative genetic finding.
Clinical Management
The suggestion of a hypothalamic defect located in the ventromedial or ventrolateral nucleus is plausible, but no such lesion has been reported, nor was such
found on careful search in a typical case (Warkany, 1970). Hamilton et al. (1972) showed that the hypogonadism is the hypogonadotropic type and the
result of hypothalamic dysfunction. Treatment with clomiphene citrate raised plasma luteinizing hormone, testosterone, and urinary gonadotropin levels to
normal and resulted in normal spermatogenesis and physical signs of puberty.
Vagotomy has been successful in correcting obesity in experimental obesity produced by hypothalamic lesions (Hirsch, 1984). Fonkalsrud and Bray (1981)
performed truncal vagotomy without pyloroplasty in a 17-year-old boy who had maintained a weight of approximately 264 lb (120 kg) for several years.
Initially, he lost weight satisfactorily but by 11 months postoperative he had regained most of the weight. Prader (1991) reported a 17-year-old boy
weighing 264 lb (120 kg) who had developed diabetes, required digitalization for cardiac failure, and presented with intolerable behavior problems. Strict
dietary control in combination with psychotherapy in a foster environment resulted in a weight reduction to 143 lb (65 kg), cessation of hyperglycemia and
glucosuria, and cardiac normalization.
Carrel et al. (1999) presented the results of a randomized controlled study of growth hormone treatment in children with Prader-Willi syndrome. They
showed that growth hormone treatment accelerated growth, decreased percent body fat, and increased fat oxidation, but did not significantly increase
resting energy expenditure. Improvements in respiratory muscle strength, physical strength, and agility also were observed, leading the authors to suggest
that growth hormone treatment may have value in reducing disability in children with PWS. Lindgren et al. (1999) measured resting ventilation, airway
occlusion pressure, and respiratory response to CO(2) in 9 children, aged 7 to 14 years, before and 6 to 9 months after the start of growth hormone therapy.
Treatment resulted in a significant increase in all 3 measurements.
Studies had shown that GH (139250) therapy with doses of GH typically used for childhood growth improves growth, body composition, physical strength
and agility, and fat utilization in children with PWS. However, these measurements remained far from normal after up to 2 years of GH therapy. Carrel et
al. (2002) assessed the effects of 24 additional months of GH treatment at varying doses on growth, body composition, strength and agility, pulmonary
function, resting energy expenditure, and fat utilization in 46 children with PWS, who had previously been treated with GH therapy for 12 to 24 months.
During months 24 to 48 of GH therapy, continued beneficial effects on body composition (decrease in fat mass and increase in lean body mass), growth
velocity, and resting energy expenditure occurred with higher GH therapy doses, but not with the lowest dose. Bone mineral density continued to improve
at all doses of GH (P less than 0.05). Prior improvements in strength and agility that occurred during the initial 24 months were sustained but did not
improve further during the additional 24 months regardless of dose. They authors concluded that salutary and sustained GH-induced changes in growth,
body composition, bone mineral density, and physical function in children with PWS can be achieved with daily administration of GH doses greater than
or equal to 1 mg/m2.
Marzullo et al. (2007) evaluated the cardiovascular response to GH therapy in 13 adult PWS patients. GH therapy increased cardiac mass devoid of
diastolic consequences. The observation of a slight deterioration of right heart function as well as the association between IGF-I and left ventricular function
during GH therapy suggested the need for appropriate cardiac and hormonal monitoring.
With regard to genetic counseling, the type of cytogenetic aberration and molecular results determine the recurrence risk. Prenatal molecular investigation
from chorionic villi should be recommended in every case despite very low recurrence risk. Prenatal ultrasonographic studies of fetal activity may be useful
for a first screening since Prader-Willi fetuses will show diminished fetal movement during the second trimester (Schinzel, 1986). Furthermore, a molecular
examination for uniparental disomy is indicated in any pregnancy in which a CVS examination disclosed (mosaic) trisomy 15 and a subsequent cytogenetic
examination from amniocytes or fetal blood revealed a normal diploid karyotype.
Treatment with octreotide, a somatostatin (182450) agonist, decreases ghrelin (605353) concentrations in healthy and acromegalic adults and induces
weight loss in children with hypothalamic obesity. To investigate whether the high fasting ghrelin concentrations of children with PWS could be suppressed
by short-term octreotide administration, Haqq et al. (2003) treated 4 subjects with PWS with octreotide (5 microg/kg-d) for 5 to 7 days and studied ghrelin
concentration, body composition, resting energy expenditure, and GH markers. Octreotide treatment decreased mean fasting plasma ghrelin concentration
by 67% (P less than 0.05). Meal-related ghrelin suppression was still present after intervention but was blunted. Body weight, body composition, leptin,
insulin (176730), resting energy expenditure, and GH parameters did not change. However, one subject's parent noted fewer tantrums over denial of food
during octreotide intervention. The authors concluded that short-term octreotide treatment markedly decreased fasting ghrelin concentrations in children
with PWS but did not fully ablate the normal meal-related suppression of ghrelin.
Festen et al. (2006) studied the effects of GH treatment on respiratory parameters in prepubertal children with PWS. At baseline, the median apnea
hypopnea index (AHI) was 5.1 per hour, mainly due to central apneas. Six months of GH treatment did not aggravate the sleep-related breathing disorders
in young PWS children. Festen et al. (2006) concluded that monitoring during upper respiratory tract infection in PWS children should be considered.
Because of the very high (3%) annual death rate of PWS patients, with most deaths occurring during moderate infections, and because PWS patients have
hypothalamic dysregulations and show no or few signs of illness, de Lind van Wijngaarden et al. (2008) investigated whether PWS patients suffer from
central adrenal insufficiency (CAI) during stressful conditions. They found that 15 (60%) of 25 randomly selected PWS patients had CAI. De Lind van
Wijngaarden et al. (2008) concluded that the high percentage of CAI in PWS patients might explain the high rate of sudden death in these patients,
particularly during infection-related stress; the authors suggested that treatment with hydrocortisone during acute illness should be considered in PWS
patients unless CAI had been ruled out with a metyrapone test.
From a multicenter study of 38 diverse GH-deficient PWS adults, Mogul et al. (2008) concluded that GH improves body composition, normalizes
triiodothyronine (T3), and is well tolerated without glucose impairment. Mildly progressive ankle edema in 5 patients was the most serious treatment-
emergent adverse event.
Pathogenesis
Relationship of Ghrelin to Hyperphagia
To determine whether ghrelin, a GH (139250) secretagogue with orexigenic properties, is elevated in PWS, Delparigi et al. (2002) measured fasting plasma
ghrelin concentration, body composition, and subjective ratings of hunger in 7 subjects with PWS and 30 healthy subjects who had fasted overnight. The
mean plasma ghrelin concentration was higher in PWS than in the reference population and this difference remained significant after adjustment for
percentage of body fat. A positive correlation was found between plasma ghrelin and subjective ratings of hunger. The authors concluded that ghrelin is
elevated in subjects with PWS. They also suggested that ghrelin may be responsible, at least in part, for the hyperphagia observed in PWS.
Haqq et al. (2003) measured fasting serum ghrelin levels in 13 children with PWS with an average age of 9.5 years and body mass index (BMI) of 31.3
kilograms per square meter. The PWS group was compared with 4 control groups: normal weight controls, obese children, and children with melanocortin-
4 receptor (155541) mutations and leptin (164160) deficiency. Ghrelin levels in children with PWS were significantly elevated (3-4 fold) compared with BMI-
matched obese controls. The authors concluded that elevation of serum ghrelin levels to the degree documented in this study may play a role as an
orexigenic factor driving the insatiable appetite and obesity found in PWS.
Feigerlova et al. (2008) studied total plasma ghrelin levels in 40 children with PWS and 84 controls from 2 months to 17 years. Plasma ghrelin levels were
higher in children with PWS than controls, both in the youngest children below 3 years who were not receiving GH (771 vs 233 pg/ml, P less than 0.0001)
and in the children older than 3 years, all of whom were treated with GH (428 vs 159 pg/ml, P less than 0.0001). The authors concluded that plasma ghrelin
levels in children with PWS are elevated at any age, including during the first years of life, thus preceding the development of obesity.
Population Genetics
In a review, Butler (1990) estimated the frequency of PWS at about 1 in 25,000 and suggested that it is the most common syndromal cause of human
obesity. In a comprehensive survey of PWS in North Dakota, Burd et al. (1990) identified 17 affected persons, from which they derived a prevalence rate of
1 per 16,062.
Whittington et al. (2001) identified all definite or possible PWS cases in the Anglia and Oxford Health Region of the U.K. (population approximately 5
million people). From a total of 167 people referred with possible PWS, 96 were classified as having PWS on genetic and/or clinical grounds. From this,
Whittington et al. (2001) estimated a lower limit of population prevalence of 1 in 52,000 with a proposed true prevalence of 1 in 45,000; a lower limit of birth
incidence of 1 in 29,000 was also estimated.
Animal Model
Nakatsu et al. (1992) found that the mouse homolog of a human gene within the PWCR is tightly linked to the p locus, which is the site of mutations
affecting pigmentation and is often associated with neurologic abnormalities as well. The p locus is located on mouse chromosome 7 near a chromosomal
region associated with imprinting effects. Nakatsu et al. (1992) suggested that the hypopigmentation in both PWS and Angelman syndrome may result
from an imprinting effect on the human cognate of the mouse p locus.
Although representing only indirectly an animal model in the usual sense, studies focusing on the effects of imprinted genes on brain development by
examining the fate of androgenetic (Ag; duplicated paternal genome) and parthenogenetic/gynogenetic (Pg/Gg; duplicated maternal genome) cells in
chimeric mouse embryos (Keverne et al., 1996) sheds interesting light on the pathogenesis of the distinctive neuropsychologic features of PWS and
Angelman syndrome. Keverne et al. (1996) observed striking cell-autonomous differences in the role of the 2 types of uniparental cells in brain development.
Ag cells with a duplicated paternal genome contributed substantially to the hypothalamic structures and not the cerebral cortex. By contrast, Pg/Gg cells
with a duplicated maternal genome contributed substantially to the cortex, striatum, and hippocampus but not to the hypothalamic structures.
Furthermore, growth of the brain was enhanced by Pg/Gg and retarded by Ag cells. Keverne et al. (1996) proposed that genomic imprinting may represent
a change in strategy controlling brain development in mammals. In particular, genomic imprinting may have facilitated a rapid nonlinear expansion of the
brain, especially the cortex, during development over evolutionary time. It is noteworthy that Ag cells were seen predominantly in the medial preoptic area
and hypothalamus, regions of the brain concerned with neuroendocrine function and primary motivated behavior, including feeding and sexual behavior,
which are disturbed in PWS. Contrariwise, MRI shows that the sylvian fissures are anomalous in Angelman patients, who are severely mentally retarded
with speech and movement disorders, findings not inconsistent with the distribution of Pg cells.
Yang et al. (1998) created 2 deletion mutations in mice to understand PWS and the mechanism of the 'imprinting center,' or IC, which maps in part to the
promoter and first exon of the SNRPN gene (182279). Mice harboring an intragenic deletion of Snrpn were phenotypically normal, suggesting that
mutations of SNRPN are not sufficient to induce PWS. Mice with a larger deletion involving both Snrpn and the putative PWS-IC lacked expression of the
imprinted genes Zfp127 (mouse homolog of ZNF127; 176270), Ndn (602117), and lpw, and manifested several phenotypes common to PWS infants. Mice
heterozygous for the paternally inherited IC-deletion died as neonates, 72% within 48 hours. At birth, the heterozygous mutant mice were present in the
expected mendelian ratio. On the day of birth, the affected mice appeared normal but underweight. There was little hypotonia, but one consistently
observed difference was that mutant mice were unable to support themselves on their hind feet, resting on their knees instead. No genital or gonadal
hypoplasia was observed at the time of birth.
Gabriel et al. (1999) reported the characterization of a transgene insertion into mouse chromosome 7C, which resulted in mouse models for PWS and AS
dependent on the sex of the transmitting parent. Epigenotype (allelic expression and DNA methylation) and fluorescence in situ hybridization analyses
indicated that the transgene-induced mutation had generated a complete deletion of the PWS/AS homologous region but had not deleted flanking loci.
Because the intact chromosome 7, opposite the deleted homolog, maintained the correct imprint in somatic cells of PWS and AS mice and established the
correct imprint in male and female germ cells of AS mice, homologous association and replication asynchrony are not part of the imprinting mechanism.
This heritable-deletion mouse model could be particularly useful for the identification of the etiologic genes and mechanisms, phenotypic basis, and
therapeutic approaches for PWS.
Muscatelli et al. (2000) also produced mice deficient for necdin (602117), and suggested that postnatal lethality associated with loss of the paternal gene may
vary dependent on the strain. Viable necdin mutants showed a reduction in both oxytocin (167050)-producing and luteinizing hormone-releasing hormone
(LHRH; 152760)-producing neurons in hypothalamus, increased skin scraping activity, and improved spatial learning and memory. The authors proposed
that underexpression of necdin is responsible for at least a subset of the multiple clinical manifestations of PWS.
Chamberlain et al. (2004) reported survival of PWS-IC deletion mice on a variety of strain backgrounds. Expression analysis of genes affected in the PWS
region suggested that while there was low expression from both parental alleles in PWS-IC deletion pups, this expression did not explain their survival on
certain strain backgrounds. Rather, the data provided evidence for strain-specific modifier genes that supported the survival of PWS-IC deletion mice.
Lee et al. (2005) demonstrated that morphologic abnormalities in axonal outgrowth and fasciculation manifested in several regions of the nervous system in
Ndn (602117)-null mouse embryos, including axons of sympathetic, retinal ganglion cell, serotonergic, and catecholaminergic neurons. Lee et al. (2005)
concluded that necdin mediates intracellular processes essential for neurite outgrowth and that loss of necdin may impinge on axonal outgrowth, and
further suggested that loss of necdin may contribute to the neurologic phenotype of PWS. They speculated that codeletion of necdin and the related protein
Magel2 (605283) may explain the lack of single gene mutations in PWS.
History
Langdon-Down (1828-1896), who described 'mongolism' (Down syndrome), also described PWS (Down, 1887) about 70 years before Prader et al. (1956),
and called it polysarcia (see account by Brain, 1967). The patient was a mentally subnormal girl who, when 13 years old, was 4 feet 4 inches tall (1.32 m)
and weighed 196 lbs (84 kg). At 25 years of age she weighed 210 lbs (95.4 kg). 'Her feet and hands remained small, and contrasted remarkably with the
appendages they terminated. She had no hair in the axillae, and scarcely any on the pubis. She had never menstruated, nor did she exhibit the slightest
sexual instinct.'
See Also:
Bray et al. (1983); Burke et al. (1987); Butler et al. (1982); Butler et al. (1982); Butler and Palmer (1983); Butler and Palmer (1983); Carpenter (1994); Cassidy
(1987); Cassidy et al. (1984); Charrow et al. (1983); Donlon et al. (1986); Duckett et al. (1984); Dunn (1968); Fraccaro et al. (1983); Fryns (1988); Fuhrmann-
Rieger et al. (1984); Futterweit et al. (1986); Gabilan and Royer (1968); Gregory et al. (1990); Gregory et al. (1991); Hawkley and Smithies (1976); Hoefnagel
et al. (1967); Holm et al. (1981); Katcher et al. (1977); Kousseff (1982); Labidi and Cassidy (1986); Laurance (1967); Laurance et al. (1981); Ledbetter et al.
(1982); Mattei et al. (1983); Mattei et al. (1984); Michaelsen et al. (1979); Nicholls et al. (1989); Orenstein et al. (1980); Qumsiyeh et al. (1992); Reed and
Butler (1984); Ridler et al. (1971); Rivera et al. (1990); Robinson et al. (1993); Robinson et al. (1993); Robinson et al. (1993); Seyler et al. (1979); Smith et al.
(1991); Trent et al. (1991); Veenema et al. (1984); Zellweger and Schneider (1968)
REFERENCES
1. American Society of Human Genetics/American College of Medical Genetics Test and Technology Transfer Committee. Diagnostic testing for
Prader-Willi and Angelman syndromes. Am. J. Hum. Genet. 58: 1085-1088, 1996. [PubMed: 8651269, related citations]
2. Amos-Landgraf, J. M., Ji, Y., Gottlieb, W., Depinet, T., Wandstrat, A. E., Cassidy, S. B., Driscoll, D. J., Rogan, P. K., Schwartz, S., Nicholls, R. D.
Chromosome breakage in the Prader-Willi and Angelman syndromes involves recombination between large, transcribed repeats at
proximal and distal breakpoints. Am. J. Hum. Genet. 65: 370-386, 1999. [PubMed: 10417280, related citations] [Full Text: Elsevier Science]
3. Bhargava, S. A., Putnam, P. E., Kocoshis, S. A., Rowe, M., Hanchett, J. M. Rectal bleeding in Prader-Willi syndrome. Pediatrics 97: 265-267, 1996.
[PubMed: 8584392, related citations]
4. Bielinska, B., Blaydes, S. M., Buiting, K., Yang, T., Krajewska-Walasek, M., Horsthemke, B., Brannan, C. I. De novo deletions of SNRPN exon 1 in
early human and mouse embryos result in a paternal to maternal imprint switch. Nature Genet. 25: 74-78, 2000. Note: Erratum: Nature
Genet. 25: 241 only, 2000. [PubMed: 10802660, related citations] [Full Text: Nature Publishing Group]
5. Bittel, D. C., Kibiryeva, N., Talebizadeh, Z., Butler, M. G. Microarray analysis of gene/transcript expression in Prader-Willi syndrome:
deletion versus UPD. J. Med. Genet. 40: 568-574, 2003. [PubMed: 12920063, related citations] [Full Text: HighWire Press]
6. Boccaccio, I., Glatt-Deeley, H., Watrin, F., Roeckel, N., Lalande, M., Muscatelli, F. The human MAGEL2 gene and its mouse homologue are
paternally expressed and mapped to the Prader-Willi region. Hum. Molec. Genet. 8: 2497-2505, 1999. [PubMed: 10556298, related citations]
[Full Text: HighWire Press]
7. Boer, H., Holland, A., Whittington, J., Butler, J., Webb, T., Clarke, D. Psychotic illness in people with Prader Willi syndrome due to
chromosome 15 maternal uniparental disomy. Lancet 359: 135-136, 2002. [PubMed: 11809260, related citations] [Full Text: Elsevier Science]
8. Brain, R. T. Historical introduction.In: Wolstenholme, G. E. W.; Porter, R. (eds.) : Mongolism. Boston: Little, Brown and Co. (pub.) 1967. Pp. 1-
5.
9. Bray, G. A., Dahms, W. T., Swerdloff, R. S., Fiser, R. H., Atkinson, R. L., Carrel, R. E. The Prader-Willi syndrome: a study of 40 patients and a
review of the literature. Medicine 62: 59-80, 1983. [PubMed: 6338343, related citations]
10. Buehler, E. M., Rossier, R., Bodis, I., Vulliet, V., Buehler, U. K., Stalder, G. Chromosomal translocation in a mentally deficient child with
cryptorchidism. Acta Paediat. Scand. 52: 177-182, 1963.
11. Buiting, K., Dittrich, B., Gross, S., Greger, V., Lalande, M., Robinson, W., Mutirangura, A., Ledbetter, D., Horsthemke, B. Molecular definition of
the Prader-Willi syndrome chromosome region and orientation of the SNRPN gene. Hum. Molec. Genet. 2: 1991-1994, 1993. [PubMed:
8111365, related citations] [Full Text: HighWire Press]
12. Buiting, K., Dittrich, B., Gross, S., Lich, C., Farber, C., Buchholz, T., Smith, E., Reis, A., Burger, J., Nothen, M. M., Barth-Witte, U., Janssen, B., and 22
others. Sporadic imprinting defects in Prader-Willi syndrome and Angelman syndrome: implications for imprint-switch models, genetic
counseling, and prenatal diagnosis. Am. J. Hum. Genet. 63: 170-180, 1998. [PubMed: 9634532, related citations] [Full Text: Elsevier Science]
13. Buiting, K., Greger, V., Brownstein, B. H., Mohr, R. M., Voiculescu, I., Winterpacht, A., Zabel, B., Horsthemke, B. A putative gene family in 15q11-
13 and 16p11.2: possible implications for Prader-Willi and Angelman syndromes. Proc. Nat. Acad. Sci. 89: 5457-5461, 1992. [PubMed:
14. Buiting, K., Gross, S., Lich, C., Gillessen-Kaesbach, G., El-Maarri, O., Horsthemke, B. Epimutations in Prader-Willi and Angelman syndromes: a
molecular study of 136 patients with an imprinting defect. Am. J. Hum. Genet. 72: 571-577, 2003. [PubMed: 12545427, related citations] [Full
Text: Elsevier Science]
15. Burd, L., Vesely, B., Martsolf, J., Kerbeshian, J. Prevalence study of Prader-Willi syndrome in North Dakota. Am. J. Med. Genet. 37: 97-99, 1990.
16. Burke, C. M., Kousseff, B. G., Gleeson, M., O'Connell, B. M., Devlin, J. G. Familial Prader-Willi syndrome. Arch. Intern. Med. 147: 673-675, 1987.
[PubMed: 3827455, related citations] [Full Text: HighWire Press]
17. Butler, M. G. Prader-Willi syndrome: current understanding of cause and diagnosis. Am. J. Med. Genet. 35: 319-332, 1990. [PubMed: 2309779,
related citations]
18. Butler, M. G. Hypopigmentation: a common feature of Prader-Labhart-Willi syndrome. Am. J. Hum. Genet. 45: 140-146, 1989. [PubMed:
2741944, related citations]
19. Butler, M. G., Kaler, S. G., Yu, P. L., Meaney, F. J. Metacarpophalangeal pattern profile analysis in Prader-Willi syndrome. Clin. Genet. 22:
315-320, 1982. [PubMed: 7160103, related citations]
20. Butler, M. G., Meaney, F. J. An anthropometric study of 38 individuals with Prader-Labhart-Willi syndrome. Am. J. Med. Genet. 26: 445-455,
1987. [PubMed: 3812595, related citations]
21. Butler, M. G., Meaney, F. J., Kaler, S. G., Yu, P. L., Palmer, C. G. Clinical differences between chromosome 15q deletion and nondeletion
Prader-Willi individuals. (Abstract) Am. J. Hum. Genet. 34: 119A only, 1982.
22. Butler, M. G., Meaney, F. J., Palmer, C. G. Clinical and cytogenetic survey of 39 individuals with Prader-Labhart-Willi syndrome. Am. J.
Med. Genet. 23: 793-809, 1986. [PubMed: 3953677, related citations]
23. Butler, M. G., Palmer, C. G. Paternal origin of chromosome 15 deletion in Prader-Willi syndrome. (Abstract) Am. J. Hum. Genet. 35: 128A
only, 1983.
24. Butler, M. G., Palmer, C. G. Parental origin of chromosome 15 deletion in Prader-Willi syndrome. (Letter) Lancet 321: 1285-1286, 1983. Note:
Originally Volume I. [PubMed: 6134086, related citations]
25. Carpenter, P. K. Prader-Willi syndrome in old age. J. Intellect. Disabil. Res. 38: 529-531, 1994. [PubMed: 7841690, related citations]
26. Carrel, A. L., Myers, S. E., Whitman, B. Y., Allen, D. B. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J. Clin.
Endocr. Metab. 87: 1581-1585, 2002. [PubMed: 11932286, related citations] [Full Text: HighWire Press]
27. Carrel, A. L., Myers, S. E., Whitman, B. Y., Allen, D. B. Growth hormone improves body composition, fat utilization, physical strength and
agility, and growth in Prader-Willi syndrome: a controlled study. J. Pediat. 134: 215-221, 1999. [PubMed: 9931532, related citations] [Full Text:
Elsevier Science]
28. Carrozzo, R., Rossi, E., Christian, S. L., Kittikamron, K., Livieri, C., Corrias, A., Pucci, L., Fois, A., Simi, P., Bosio, L., Beccaria, L., Zuffardi, O.,
Ledbetter, D. H. Inter- and intrachromosomal rearrangements are both involved in the origin of 15q11-q13 deletions in Prader-Willi
syndrome. (Letter) Am. J. Hum. Genet. 61: 228-231, 1997. [PubMed: 9246004, related citations] [Full Text: Elsevier Science]
29. Cassidy, S. B. Recurrence risk in Prader-Willi syndrome. (Letter) Am. J. Med. Genet. 28: 59-60, 1987. [PubMed: 3674119, related citations]
30. Cassidy, S. B. Prader-Willi syndrome. J. Med. Genet. 34: 917-923, 1997. [PubMed: 9391886, related citations] [Full Text: HighWire Press]
31. Cassidy, S. B. Prader-Willi syndrome: characteristics, management, and etiology. Ala. J. Med. Sci. 24: 169-175, 1987. [PubMed: 3578708, related
citations]
32. Cassidy, S. B., Forsythe, M., Heeger, S., Nicholls, R. D., Schork, N., Benn, P., Schwartz, S. Comparison of phenotype between patients with
Prader-Willi syndrome due to deletion 15q and uniparental disomy 15. Am. J. Med. Genet. 68: 433-440, 1997. [PubMed: 9021017, related
citations] [Full Text: John Wiley & Sons, Inc.]
33. Cassidy, S. B., Gainey, A. J., Butler, M. G. Occupational hydrocarbon exposure among fathers of Prader-Willi syndrome patients with and
without deletions of 15q. Am. J. Hum. Genet. 44: 806-810, 1989. [PubMed: 2729276, related citations]
34. Cassidy, S. B., Lai, L.-W., Erickson, R. P., Magnuson, L., Thomas, E., Gendron, R., Herrmann, J. Trisomy 15 with loss of the paternal 15 as a
cause of Prader-Willi syndrome due to maternal disomy. Am. J. Hum. Genet. 51: 701-708, 1992. [PubMed: 1357962, related citations]
35. Cassidy, S. B., McKillop, J. A. Temperature regulation in Prader-Willi syndrome. (Abstract) Am. J. Med. Genet. 41: 528 only, 1991.
36. Cassidy, S. B., Schwartz, S. Prader-Willi and Angelman syndromes: disorders of genomic imprinting. Medicine 77: 140-151, 1998. [PubMed:
9556704, related citations] [Full Text: Lippincott Williams & Wilkins]
37. Cassidy, S. B., Thuline, H. C., Holm, V. A. Deletion of chromosome 15(q11-13) in a Prader-Labhart-Willi syndrome clinic population. Am. J.
38. Chamberlain, S. J., Johnstone, K. A., DuBose, A. J., Simon, T. A., Bartolomei, M. S., Resnick, J. L., Brannan, C. I. Evidence for genetic modifiers of
postnatal lethality in PWS-IC deletion mice. Hum. Molec. Genet. 13: 2971-2977, 2004. [PubMed: 15459179, related citations] [Full Text: HighWire
Press]
39. Charrow, J., Balkin, N., Cohen, M. M. Translocations in Prader-Willi syndrome. Clin. Genet. 23: 304-307, 1983. [PubMed: 6851221, related
citations]
40. Chitayat, D., Davis, E. B., McGillivray, B. C., Hayden, M. R., Hall, J. G. Perinatal and first year follow-up of patients with Prader-Willi
syndrome: normal size of hands and feet. Clin. Genet. 35: 161-166, 1989. [PubMed: 2706799, related citations]
41. Clarren, S. K., Smith, D. W. Prader-Willi syndrome: variable severity and recurrence risk. Am. J. Dis. Child. 131: 798-800, 1977. [PubMed:
42. Clayton-Smith, J., Driscoll, D. J., Waters, M. F., Webb, T., Andrews, T., Malcolm, S., Pembrey, M. E., Nicholls, R. D. Difference in methylation
patterns within the D15S9 region of chromosome 15q11-13 in first cousins with Angelman syndrome and Prader-Willi syndrome. Am. J.
43. Creel, D. J., Bendel, C. M., Wiesner, G. L., Wirtschafter, J. D., Arthur, D. C., King, R. A. Abnormalities of the central visual pathways in Prader-
Willi syndrome associated with hypopigmentation. New Eng. J. Med. 314: 1606-1609, 1986. [PubMed: 3713758, related citations] [Full Text:
Atypon]
44. Curfs, L. M. G., Verhulst, F. C., Fryns, J. P. Behavioral and emotional problems in youngsters with Prader-Willi syndrome. Genetic
Counseling 2: 33-41, 1991. [PubMed: 1741975, related citations]
45. Curfs, L. M. G., Wiegers, A. M., Sommers, J. R. M., Borghgraef, M., Fryns, J. P. Strengths and weaknesses in the cognitive profile of
youngsters with Prader-Willi syndrome. Clin. Genet. 40: 430-434, 1991. [PubMed: 1778005, related citations]
46. Davies, H. D., Leusink, G. L., McConnell, A., Deyell, M., Cassidy, S. B., Fick, G. H., Coppes, M. J. Myeloid leukemia in Prader-Willi syndrome. J.
Pediat. 142: 174-178, 2003. [PubMed: 12584540, related citations] [Full Text: Elsevier Science]
47. DeFraites, E. B., Thurmon, T. F., Farhadian, H. Familial Prader-Willi syndrome.In: Bergsma, D. : Genetic Forms of Hypogonadism. New
York: National Foundation-March of Dimes (pub.) 1975. Pp. 123-126.
48. de Lind van Wijngaarden, R. F. A., Otten, B. J., Festen, D. A. M., Joosten, K. F. M., de Jong, F. H., Sweep, F. C. G. J., Hokken-Koelega, A. C. S. High
prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J. Clin. Endocr. Metab. 93: 1649-1654, 2008. [PubMed:
49. Delparigi, A., Tschop, M., Heiman, M. L., Salbe, A. D., Vozarova, B., Sell, S. M., Bunt, J. C., Tataranni, P. A. High circulating ghrelin: a potential
cause for hyperphagia and obesity in Prader-Willi syndrome. J. Clin. Endocr. Metab. 87: 5461-5464, 2002. [PubMed: 12466337, related citations]
[Full Text: HighWire Press]
50. de Smith, A. J., Purmann, C., Walters, R. G., Ellis, R. J., Holder, S. E., Van Haelst, M. M., Brady, A. F., Fairbrother, U. L., Dattani, M., Keogh, J. M.,
Henning, E., Yeo, G. S. H., O'Rahilly, S., Froguel, P., Farooqi, I. S., Blakemore, A. I. F. A deletion of the HBII-85 class of small nucleolar RNAs
(snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum. Molec. Genet. 18: 3257-3265, 2009. [PubMed: 19498035, related
citations] [Full Text: HighWire Press]
51. Devriendt, K., Petit, P., Matthijs, G., Vermeesch, J. R., Holvoet, M., De Muelenaere, A., Marynen, P., Cassiman, J.-J., Fryns, J.-P. Trisomy 15 rescue
with jumping translocation of distal 15q in Prader-Willi syndrome. J. Med. Genet. 34: 395-399, 1997. [PubMed: 9152837, related citations] [Full
Text: HighWire Press]
52. Dittrich, B., Robinson, W. P., Knoblauch, H., Buiting, K., Schmidt, K., Gillessen-Kaesbach, G., Horsthemke, B. Molecular diagnosis of the Prader-
Willi and Angelman syndromes by detection of parent-of-origin specific DNA methylation in 15q11-13. Hum. Genet. 90: 313-315, 1992.
53. Donlon, T. A., Lalande, M., Wyman, A., Bruns, G., Latt, S. A. Isolation of molecular probes associated with the chromosome 15 instability in
the Prader-Willi syndrome. Proc. Nat. Acad. Sci. 83: 4408-4412, 1986. Note: Erratum: Proc. Nat. Acad. Sci. 83: 6964 only, 1986. [PubMed:
54. Down, J. L. Mental Affections of Childhood and Youth. London: Churchill (pub.) 1887. P. 172.
55. Driscoll, D. J., Waters, M. F., Williams, C. A., Zori, R. T., Glenn, C. C., Avidano, K. M., Nicholls, R. D. A DNA methylation imprint, determined
by the sex of the parent, distinguishes the Angelman and Prader-Willi syndromes. Genomics 13: 917-924, 1992. [PubMed: 1505981, related
citations]
56. Duckett, D. P., Roberts, S. H., Davies, P. Unbalanced reciprocal translocations in cases of Prader-Willi syndrome. Hum. Genet. 67: 156-161,
57. Dunn, H. G. The Prader-Labhart-Willi syndrome: review of the literature and report of nine cases. Acta Paediat. Scand. 186 (suppl.): 1-38,
1968.
58. Eiholzer, U., Blum, W. F., Molinari, L. Body fat determined by skinfold measurements is elevated despite underweight in infants with
Prader-Labhart-Willi syndrome. J. Pediat. 134: 222-225, 1999. [PubMed: 9931533, related citations] [Full Text: Elsevier Science]
59. Faivre, L., Cormier-Daire, V., Lapierre, J. M., Colleaux, L., Jacquemont, S., Genevieve, D., Saunier, P., Munnich, A., Turleau, C., Romana, S., Prieur,
M., de Blois, M. C., Vekemans, M. Deletion of the SIM1 gene (6q16.2) in a patient with a Prader-Willi-like phenotype. (Letter) J. Med. Genet.
39: 594-596, 2002. Note: Erratum: J. Med. Genet. 41: 320 only, 2004. [PubMed: 12161602, related citations] [Full Text: HighWire Press]
60. Fan, Z., Greenwood, R., Fisher, A., Pendyal, S., Powell, C. M. Characteristics and frequency of seizure disorder in 56 patients with Prader-
Willi syndrome. (Letter) Am. J. Med. Genet. 149A: 1581-1584, 2009. [PubMed: 19533781, related citations] [Full Text: John Wiley & Sons, Inc.]
61. Feigerlova, E., Diene, G., Conte-Auriol, F., Molinas, C., Gennero, I., Salles, J.-P., Arnaud, C., Tauber, M. Hyperghrelinemia precedes obesity in
Prader-Willi syndrome. J. Clin. Endocr. Metab. 93: 2800-2805, 2008. [PubMed: 18460565, related citations] [Full Text: HighWire Press]
62. Fernandez, F., Berry, C., Mutton, D. Prader-Willi syndrome in siblings, due to unbalanced translocation between chromosomes 15 and 22.
Arch. Dis. Child. 62: 841-843, 1987. [PubMed: 3662590, related citations]
63. Festen, D. A. M., de Weerd, A. W., van den Bossche, R. A. S., Joosten, K., Hoeve, H., Hokken-Koelega, A. C. S. Sleep-related breathing disorders
in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. J. Clin. Endocr. Metab. 91: 4911-4915, 2006.
64. Fleischer-Michaelsen, K., Lundsteen, C., Hansen, F. J. Prader-Willi syndrome and chromosomal mosaicism 46,XY/47,XY,+mar in two cases.
Clin. Genet. 16: 147-150, 1979. [PubMed: 573673, related citations]
65. Fonkalsrud, E. W., Bray, G. Vagotomy for treatment of obesity in childhood due to Prader-Willi syndrome. J. Pediat. Surg. 16: 888-889, 1981.
66. Fraccaro, M., Zuffardi, O., Buhler, E., Schinzel, A., Simoni, G., Witkowski, R., Bonifaci, E., Caufin, D., Cignacco, G., Delendi, N., Gargantini, L.,
Losanowa, T., Marca, L., Ullrich, E., Vigi, V. Deficiency, transposition, and duplication of one 15q region may be alternatively associated
with Prader-Willi (or a similar) syndrome: analysis of seven cases after varying ascertainment. Hum. Genet. 64: 388-394, 1983. [PubMed:
67. Fryns, J.-P., Bettens, W., Van den Berghe, H. Distal deletion of the long arm of chromosome 6: a specific phenotype? Am. J. Med. Genet. 24:
68. Fryns, J. P. The Prader-Willi syndrome and the Sotos syndrome: syndromes or sequences? (Letter) Clin. Genet. 33: 457-458, 1988. [PubMed:
69. Fuhrmann-Rieger, A., Kohler, A., Fuhrmann, W. Duplication or insertion in 15q11-13 associated with mental retardation--short stature and
obesity--Prader-Willi or Cohen syndrome? Clin. Genet. 25: 347-352, 1984. [PubMed: 6713711, related citations]
70. Fujita, H., Sakamoto, Y., Hamamoto, Y. An extra idic(15p)(q11) chromosome in Prader-Willi syndrome. Hum. Genet. 55: 409-411, 1980.
71. Fulmer-Smentek, S. B., Francke, U. Association of acetylated histones with paternally expressed genes in the Prader-Willi deletion region.
Hum. Molec. Genet. 10: 645-652, 2001. [PubMed: 11230184, related citations] [Full Text: HighWire Press]
72. Futterweit, W., Ritch, R., Teekhasaenee, C., Nelson, E. S. Coexistence of Prader-Willi syndrome, congenital ectropion uveae with glaucoma,
and factor XI deficiency. JAMA 255: 3280-3282, 1986. [PubMed: 3086578, related citations]
73. Gabilan, J. C. Syndrome de Prader, Labhardt et Willi. J. Pediat. (Paris) 1: 179, 1962.
74. Gabilan, J. C., Royer, P. Le syndrome de Prader, Labhardt et Willi (etude de onze observations). Arch. Franc. Pediat. 25: 121-149, 1968.
75. Gabriel, J. M., Merchant, M., Ohta, T., Ji, Y., Caldwell, R. G., Ramsey, M. J., Tucker, J. D., Longnecker, R., Nicholls, R. D. A transgene insertion
creating a heritable chromosome deletion mouse model of Prader-Willi and Angelman syndromes. Proc. Nat. Acad. Sci. 96: 9258-9263,
1999. [PubMed: 10430930, related citations] [Full Text: HighWire Press]
76. Gilhuis, H. J., van Ravenswaaij, C. M., Hamel, B. J. C., Gabreels, F. J. M. Interstitial 6q deletion with a Prader-Willi-like phenotype: a new case
and review of the literature. Europ. J. Paediat. Neurol. 4: 39-43, 2000. [PubMed: 10701104, related citations] [Full Text: Elsevier Science]
77. Glenn, C. C., Nicholls, R. D., Robinson, W. P., Saitoh, S., Niikawa, N., Schinzel, A., Horsthemke, B., Driscoll, D. J. Modification of the DNA
methylation imprint in unique Angelman and Prader-Willi patients. Hum. Molec. Genet. 2: 1377-1382, 1993. [PubMed: 8242060, related
78. Gold, J.-A., Ruth, C., Osann, K., Flodman, P., McManus, B., Lee, H.-S., Donkervoort, S., Khare, M., Roof, E., Dykens, E., Driscoll, D. J., Butler, M. G.,
Heinemann, J., Cassidy, S., Kimonis, V. E. Frequency of Prader-Willi syndrome in births conceived via assisted reproductive technology.
Genet. Med. 16: 164-169, 2014. Note: Erratum: Genet. Med. 15: 912 only, 2013. [PubMed: 23928912, related citations] [Full Text: Nature Publishing
Group]
79. Greenstein, M. A. Prader-Willi and Angelman syndromes in one kindred with expression consistent with genetic imprinting. (Abstract)
Am. J. Hum. Genet. 47 (suppl.): A59 only, 1990.
80. Greenswag, L. R. Adults with Prader-Willi syndrome: a survey of 232 cases. Dev. Med. Child Neurol. 29: 145-152, 1987. [PubMed: 3582784,
related citations]
81. Gregory, C. A., Kirkilionis, A. J., Greenberg, C. R., Chudley, A. E., Hamerton, J. L. Detection of molecular rearrangements in Prader-Willi
syndrome patients by using genomic probes recognizing four loci within the PWCR. Am. J. Med. Genet. 35: 536-545, 1990. [PubMed:
82. Gregory, C. A., Schwartz, J., Kirkilionis, A. J., Rudd, N., Hamerton, J. L. Somatic recombination rather than uniparental disomy suggested as
another mechanism by which genetic imprinting may play a role in the etiology of Prader-Willi syndrome. Hum. Genet. 88: 42-48, 1991.
83. Guanti, G. A new case of rearrangement of chromosome 15 associated with Prader-Willi syndrome. Clin. Genet. 17: 423-427, 1980. [PubMed:
84. Gunay-Aygun, M., Schwartz, S., Heeger, S., O'Riordan, M. A., Cassidy, S. B. The changing purpose of Prader-Willi syndrome clinical
diagnostic criteria and proposed revised criteria. Pediatrics 108: e92, 2001. Note: Electronic Article. [PubMed: 11694676, related citations] [Full
Text: HighWire Press]
85. Hall, B. D. Leukaemia and the Prader-Willi syndrome. (Letter) Lancet 325: 46 only, 1985. Note: Originally Volume I. [PubMed: 2856967, related
citations]
86. Hall, B. D., Smith, D. W. Prader-Willi syndrome: a resume of 32 cases including an instance of affected first cousins, one of whom is of
normal stature and intelligence. J. Pediat. 81: 286-293, 1972. [PubMed: 5042487, related citations]
87. Hall, J. G. Genomic imprinting and its clinical implications. (Editorial) New Eng. J. Med. 326: 827-829, 1992. [PubMed: 1538729, related
citations] [Full Text: Atypon]
88. Hamilton, C. R., Jr., Scully, R. E., Kliman, B. Hypogonadotropism in Prader-Willi syndrome: induction of puberty and spermatogenesis by
clomiphene citrate. Am. J. Med. 52: 322-329, 1972. [PubMed: 5011391, related citations]
89. Haqq, A. M., Farooqi, I. S., O'Rahilly, S., Stadler, D. D., Rosenfeld, R. G., Pratt, K. L., LaFranchi, S. H., Purnell, J. Q. Serum ghrelin levels are
inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-
Willi syndrome. J. Clin. Endocr. Metab. 88: 174-178, 2003. [PubMed: 12519848, related citations] [Full Text: HighWire Press]
90. Haqq, A. M., Stadler, D. D., Rosenfeld, R. G., Pratt, K. L., Weigle, D. S., Frayo, R. S., Lafranchi, S. H., Cummings, D. E., Purnell, J. Q. Circulating
ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. J. Clin. Endocr. Metab. 88: 3573-
3576, 2003. [PubMed: 12915638, related citations] [Full Text: HighWire Press]
91. Hasegawa, T., Hara, M., Ando, M., Osawa, M., Fukuyama, Y., Takahashi, M., Yamada, K. Cytogenetic studies of familial Prader-Willi
syndrome. Hum. Genet. 65: 325-330, 1984. [PubMed: 6693121, related citations]
92. Hawkley, C. J., Smithies, A. The Prader-Willi syndrome with a 15-15 translocation: case report and review of the literature. J. Med. Genet.
13: 152-157, 1976. [PubMed: 933113, related citations] [Full Text: HighWire Press]
93. Hirsch, J. Personal Communication. New York, N.Y. 4/6/1984.
94. Hittner, H. M., King, R. A., Riccardi, V. M., Ledbetter, D. H., Borda, R. P., Ferrell, R. E., Kretzer, F. L. Oculocutaneous albinoidism as a
manifestation of reduced neural crest derivatives in the Prader-Willi syndrome. Am. J. Ophthal. 94: 328-337, 1982. [PubMed: 6812426, related
citations]
95. Hoefnagel, D., Costello, P. J., Hatoum, K. Prader-Willi syndrome. J. Ment. Defic. Res. 11: 1-11, 1967. [PubMed: 6068089, related citations]
96. Holder, J. L., Jr., Butte, N. F., Zinn, A. R. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum.
Molec. Genet. 9: 101-108, 2000. [PubMed: 10587584, related citations] [Full Text: HighWire Press]
97. Holm, V. A., Cassidy, S. B., Butler, M. G., Hanchett, J. M., Greenswag, L. R., Whitman, B. Y., Greenberg, F. Prader-Willi syndrome: consensus
diagnostic criteria. Pediatrics 91: 398-402, 1993. [PubMed: 8424017, related citations]
98. Holm, V. A., Sulzbacher, S. J., Pipes, P. L. Prader-Willi Syndrome. Baltimore: University Park Press (pub.) 1981.
99. Hordijk, R., Wierenga, H., Scheffer, H., Leegte, B., Hofstra, R. M. W., Stolte-Dijkstra, I. Maternal uniparental disomy for chromosome 14 in a
boy with a normal karyotype. J. Med Genet. 36: 782-785, 1999. [PubMed: 10528860, related citations] [Full Text: HighWire Press]
100. Horsthemke, B., Nazlican, H., Husing, J., Klein-Hitpass, L., Claussen, U., Michel, S., Lich, C., Gillessen-Kaesbach, G., Buiting, K. Somatic
mosaicism for maternal uniparental disomy 15 in a girl with Prader-Willi syndrome: confirmation by cell cloning and identification of
candidate downstream genes. Hum. Molec. Genet. 12: 2723-2732, 2003. [PubMed: 12944418, related citations] [Full Text: HighWire Press]
101. Horsthemke, B., Wagstaff, J. Mechanisms of imprinting of the Prader-Willi/Angelman region. Am. J. Med. Genet. 146A: 2041-2052, 2008.
[PubMed: 18627066, related citations] [Full Text: John Wiley & Sons, Inc.]
102. Hoybye, C., Hilding, A., Jacobsson, H., Thoren, M. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe
obesity. J. Clin. Endocr. Metab. 87: 3590-3597, 2002. [PubMed: 12161480, related citations] [Full Text: HighWire Press]
103. Hudgins, L., Cassidy, S. B. Hand and foot length in Prader-Willi syndrome. Am. J. Med. Genet. 41: 5-9, 1991. [PubMed: 1951464, related
citations]
104. Hudgins, L., Geer, J. S., Cassidy, S. B. Phenotypic differences in African Americans with Prader-Willi syndrome. Genet. Med. 1: 49-51, 1998.
105. Hulten, M., Armstrong, S., Challinor, P., Gould, C., Hardy, G., Leedham, P., Lee, T., McKeown, C. Genomic imprinting in an Angelman and
Prader-Willi translocation family. (Letter) Lancet 338: 638-639, 1991. [PubMed: 1679180, related citations] [Full Text: Elsevier Science]
106. Ishikawa, T., Kanayama, M., Wada, Y. Prader-Willi syndrome in two siblings: one with normal karyotype, one with a terminal deletion of
distal Xq. Clin. Genet. 32: 295-299, 1987. [PubMed: 3319293, related citations]
107. Ishikawa, T., Kibe, T., Wada, Y. Deletion of small nuclear ribonucleoprotein polypeptide N (SNRPN) in Prader-Willi syndrome detected by
fluorescence in situ hybridization: two sibs with the typical phenotype without a cytogenetic deletion in chromosome 15q. Am. J. Med.
Genet. 62: 350-352, 1996. [PubMed: 8723064, related citations]
108. Jancar, J. Prader-Willi syndrome (hypotonia, obesity, hypogonadism, growth and mental retardation). J. Ment. Defic. Res. 15: 20-29, 1971.
109. Ji, Y., Walkowicz, M. J., Buiting, K., Johnson, D. K., Tarvin, R. E., Rinchik, E. M., Horsthemke, B., Stubbs, L., Nicholls, R. O. The ancestral gene for
transcribed, low-copy repeats in the Prader-Willi/Angelman region encodes a large protein implicated in protein trafficking, which is
deficient in mice with neuromuscular and spermiogenic abnormalities. Hum. Molec. Genet. 8: 533-542, 1999. [PubMed: 9949213, related
110. Johnsen, S., Crawford, J. D., Haessler, H. A. Fasting hyperlipogenesis: an inborn error of energy metabolism in Prader-Willi syndrome..
Proc. Am. Pediat. Soc. , 1967.
111. Kaminsky, E. B., Kaul, V., Paschall, J., Church, D. M., Bunke, B., Kunig, D., Moreno-De-Luca, D., Moreno-De-Luca, A., Mulle, J. G., Warren, S. T.,
Richard, G., Compton, J. G., and 22 others. An evidence-based approach to establish the functional and clinical significance of copy number
variants in intellectual and developmental disabilities. Genet. Med. 13: 777-784, 2011. [PubMed: 21844811, related citations]
112. Kantor, B., Kaufman, Y., Makedonski, K., Razin, A., Shemer, R. Establishing the epigenetic status of the Prader-Willi/Angelman imprinting
center in the gametes and embryo. Hum. Molec. Genet. 13: 2767-2779, 2004. [PubMed: 15367489, related citations] [Full Text: HighWire Press]
113. Katcher, M. L., Bargman, G. J., Gilbert, E. F., Opitz, J. M. Absence of spermatogonia in the Prader-Willi syndrome. Europ. J. Pediat. 124: 257-
260, 1977. [PubMed: 844459, related citations]
114. Kennerknecht, I. Differentiated recurrence risk estimations in the Prader-Willi syndrome. Clin. Genet. 41: 303-308, 1992. [PubMed: 1623627,
related citations]
115. Keverne, E. B., Fundele, R., Narasimha, M., Barton, S. C., Surani, M. A. Genomic imprinting and the differential roles of parental genomes in
brain development. Develop. Brain Res. 92: 91-100, 1996.
116. Kim, S.-J., Miller, J. L., Kuipers, P. J., German, J. R., Beaudet, A. L., Sahoo, T., Driscoll, D. J. Unique and atypical deletions in Prader-Willi
syndrome reveal distinct phenotypes. Europ. J. Hum. Genet. 20: 283-290, 2012. [PubMed: 22045295, related citations] [Full Text: Nature
Publishing Group]
117. Kirkilionis, A. J., Gregory, C. A., Hamerton, J. L. Long-range restriction mapping and linkage analysis of the Prader-Willi chromosome
region (PWCR). Genomics 9: 524-535, 1991. [PubMed: 2032723, related citations] [Full Text: Elsevier Science]
118. Kishore, S., Khanna, A., Zhang, Z., Hui, J., Balwierz, P. J., Stefan, M., Beach, C., Nicholls, R. D., Zavolan, M., Stamm, S. The snoRNA MBII-52
(SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum. Molec. Genet. 19: 1153-1164, 2010. [PubMed:
119. Kishore, S., Stamm, S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 311: 230-232, 2006. [PubMed:
120. Knoll, J. H. M., Sinnett, D., Wagstaff, J., Glatt, K., Schantz-Wilcox, A., Whiting, P. M., Wingrove, P., Sikela, J. M., Lalande, M. FISH ordering of
reference markers and of the gene for the a5 subunit of the g-aminobutyric acid receptor (GABRA5) with the Angelman and Prader-
Willi syndrome chromosomal regions. Hum. Molec. Genet. 2: 183-189, 1993. [PubMed: 8388764, related citations] [Full Text: HighWire Press]
121. Kousseff, B. G. The cytogenetic controversy in the Prader-Labhart-Willi syndrome. Am. J. Med. Genet. 13: 431-439, 1982. [PubMed: 7158643,
related citations]
122. Kubota, T., Sutcliffe, J. S., Aradhya, S., Gillessen-Kaesbach, G., Christian, S. L., Horsthemke, B., Beaudet, A. L., Ledbetter, D. H. Validation studies
of SNRPN methylation as a diagnostic test for Prader-Willi syndrome. Am. J. Med. Genet. 66: 77-80, 1996. [PubMed: 8957518, related citations]
123. Kucerova, M., Strakova, M., Polivkova, Z. The Prader-Willi syndrome with a 15-3 translocation. J. Med. Genet. 16: 234-235, 1979. [PubMed:
124. Kuwano, A., Mutirangura, A., Dittrich, B., Buiting, K., Horsthemke, B., Saitoh, S., Niikawa, N., Ledbetter, S. A., Greenberg, F., Chinault, A. C.,
Ledbetter, D. H. Molecular dissection of the Prader-Willi/Angelman syndrome region (15q11-13) by YAC cloning and FISH analysis. Hum.
Molec. Genet. 1: 417-425, 1992. Note: Erratum: Hum. Molec. Genet. 1: 784 only, 1992. [PubMed: 1363801, related citations] [Full Text: HighWire
Press]
125. Labidi, F., Cassidy, S. B. A blind prometaphase study of Prader-Willi syndrome: frequency and consistency in interpretation of del 15q.
Am. J. Hum. Genet. 39: 452-460, 1986. [PubMed: 3464201, related citations]
126. Lakich, D., Kazazian, H. H., Jr., Antonarakis, S. E., Gitschier, J. Inversions disrupting the factor VIII gene are a common cause of severe
haemophilia A. Nature Genet. 5: 236-241, 1993. [PubMed: 8275087, related citations] [Full Text: Nature Publishing Group]
127. Latt, S. A., Tantravahi, U., Nicholls, R., Ringer, S., Stroh, H., Fuller, R., Neve, R., Kaplan, L., Wharton, R. Mapping, characterization, and
diagnostic utilization of 10 DNA segments from the proximal long arm of human chromosome 15. (Abstract) Cytogenet. Cell Genet. 46: 644
only, 1987.
128. Laurance, B. M. Hypotonia, mental retardation, obesity, and cryptorchidism associated with dwarfism and diabetes in children. Arch. Dis.
Child. 42: 126-139, 1967. [PubMed: 4381583, related citations]
129. Laurance, B. M., Brito, A., Wilkinson, J. Prader-Willi syndrome after age 15 years. Arch. Dis. Child. 56: 181-186, 1981. [PubMed: 7212756, related
citations]
130. Ledbetter, D. H., Greenberg, F., Holm, V. A., Cassidy, S. B. Conference report: second annual Prader-Willi scientific conference. Am. J. Med.
131. Ledbetter, D. H., Mascarello, J. T., Riccardi, V. M., Harper, V. D., Airhart, S. D., Strobel, R. J. Chromosome 15 abnormalities and the Prader-Willi
syndrome: a follow-up report of 40 cases. Am. J. Hum. Genet. 34: 278-285, 1982. [PubMed: 7072717, related citations]
132. Ledbetter, D. H., Riccardi, V. M., Airhart, S. D., Strobel, R. J., Keenan, B. S., Crawford, J. D. Deletions of chromosome 15 as a cause of the
Prader-Willi syndrome. New Eng. J. Med. 304: 325-329, 1981. [PubMed: 7442771, related citations] [Full Text: Atypon]
133. Ledbetter, D. H., Riccardi, V. M., Youngbloom, S. A., Strobel, R. J., Keenan, B. S., Crawford, J. D., Louro, J. M. Deletion (15q) as a cause of the
Prader-Willi syndrome (PWS). (Abstract) Am. J. Hum. Genet. 32: 77A only, 1980.
134. Lee, S., Kozlov, S., Hernandez, L., Chamberlain, S.J., Brannan, C. I., Stewart, C. L., Wevrick, R. Expression and imprinting of MAGEL2 suggest
a role in Prader-Willi syndrome and the homologous murine imprinting phenotype. Hum. Molec. Genet. 9: 1813-1819, 2000. [PubMed:
135. Lee, S., Walker, C. L., Karten, B., Kuny, S. L., Tennese, A. A., O'Neill, M. A., Wevrick, R. Essential role for the Prader-Willi syndrome protein
necdin in axonal outgrowth. Hum. Molec. Genet. 14: 627-637, 2005. [PubMed: 15649943, related citations] [Full Text: HighWire Press]
136. Lee, S., Wevrick, R. Identification of novel imprinted transcripts in the Prader-Willi syndrome and Angelman syndrome deletion region:
further evidence for regional imprinting control. Am. J. Hum. Genet. 66: 848-858, 2000. [PubMed: 10712201, related citations] [Full Text:
Elsevier Science]
137. Lehrman, M. A., Goldstein, J. L., Russell, D. W., Brown, M. S. Duplication of seven exons in LDL receptor gene caused by Alu-Alu
recombination in a subject with familial hypercholesterolemia. Cell 48: 827-835, 1987. [PubMed: 3815525, related citations] [Full Text: Elsevier
Science]
138. Lindgren, A. C., Barkeling, B., Hagg, A., Ritzen, E. M., Marcus, C., Rossner, S. Eating behavior in Prader-Willi syndrome, normal weight, and
obese control groups. J. Pediat. 137: 50-55, 2000. [PubMed: 10891821, related citations] [Full Text: Elsevier Science]
139. Lindgren, A. C., Hellstrom, L. G., Ritzen, E. M., Milerad, J. Growth hormone treatment increases CO(2) response, ventilation and central
inspiratory drive in children with Prader-Willi syndrome. Europ. J. Pediat. 158: 936-940, 1999. [PubMed: 10541953, related citations] [Full Text:
Springer]
140. Lubinsky, M., Zellweger, H., Greenswag, L., Larson, G., Hansmann, I., Ledbetter, D. Familial Prader-Willi syndrome with apparently normal
chromosomes. Am. J. Med. Genet. 28: 37-43, 1987. [PubMed: 3674116, related citations]
141. MacMillan, D. R., Kim, C. B., Weisskopf, B. Syndrome of growth resistance, obesity, and intellectual impairment with precocious puberty.
Arch. Dis. Child. 47: 119-121, 1972. [PubMed: 5018626, related citations]
142. Magenis, R. E., Toth-Fejel, S., Allen, L. J., Black, M., Brown, M. G., Budden, S., Cohen, R., Friedman, J. M., Kalousek, D., Zonana, J., Lacy, D.,
LaFranchi, S., Lahr, M., Macfarlane, J., Williams, C. P. S. Comparison of the 15q deletions in Prader-Willi and Angelman syndromes: specific
regions, extent of deletions, parental origin, and clinical consequences.. Am. J. Med. Genet. 35: 333-349, 1990. [PubMed: 2309780, related
citations]
143. Marcus, S., Hellgren, D., Lambert, B., Fallstrom, S. P., Wahlstrom, J. Duplication in the hypoxanthine phosphoribosyl-transferase gene
caused by Alu-Alu recombination in a patient with Lesch Nyhan syndrome. Hum. Genet. 90: 477-482, 1993. [PubMed: 8381385, related
citations]
144. Marzullo, P., Marcassa, C., Campini, R., Eleuteri, E., Minocci, A., Sartorio, A., Vettor, R., Liuzzi, A., Grugni, G. Conditional cardiovascular
response to growth hormone therapy in adult patients with Prader-Willi syndrome. J. Clin. Endocr. Metab. 92: 1364-1371, 2007. [PubMed:
145. Mascari, M. J., Gottlieb, W., Rogan, P. K., Butler, M. G., Waller, D. A., Armour, J. A. L., Jeffreys, A. J., Ladda, R. L., Nicholls, R. D. The frequency of
uniparental disomy in Prader-Willi syndrome: implications for molecular diagnosis. New Eng. J. Med. 326: 1599-1607, 1992. [PubMed:
1584261, related citations] [Full Text: Atypon]
146. Mattei, J. F., Mattei, M. G., Giraud, F. Prader-Willi syndrome and chromosome 15: a clinical discussion of 20 cases. Hum. Genet. 64: 356-362,
147. Mattei, M. G., Souiah, N., Mattei, J. F. Chromosome 15 anomalies and the Prader-Willi syndrome: cytogenetic analysis. Hum. Genet. 66: 313-
148. McEntagart, M. E., Webb, T., Hardy, C., King, M. D. Familial Prader-Willi syndrome: case report and a literature review. Clin. Genet. 58: 216-
223, 2000. [PubMed: 11076044, related citations] [Full Text: Blackwell Publishing]
149. Meguro, M., Mitsuya, K., Nomura, N., Kohda, M., Kashiwagi, A., Nishigaki, R., Yoshioka, H., Nakao, M., Oishi, M., Oshimura, M. Large-scale
evaluation of imprinting status in the Prader-Willi syndrome region: an imprinted direct repeat cluster resembling small nucleolar RNA
genes. Hum. Molec. Genet. 10: 383-394, 2001. [PubMed: 11157801, related citations] [Full Text: HighWire Press]
150. Michaelsen, K. F., Lundsteen, C., Hansen, F. J. Prader-Willi syndrome and chromosomal mosaicism 46, XY-47, XY, +mar in two cases. Clin.
151. Miller, J. L., Couch, J. A., Schmalfuss, I., He, G., Liu, Y., Driscoll, D. J. Intracranial abnormalities detected by three-dimensional magnetic
resonance imaging in Prader-Willi syndrome. Am. J. Med. Genet. 143A: 476-483, 2007. [PubMed: 17103438, related citations] [Full Text: John
Wiley & Sons, Inc.]
152. Miller, S. P., Riley, P., Shevell, M. I. The neonatal presentation of Prader-Willi syndrome revisited. J. Pediat. 134: 226-228, 1999. [PubMed:
9931534, related citations] [Full Text: Elsevier Science]
153. Ming, J. E., Blagowidow, N., Knoll, J. H. M., Rollings, L., Fortina, P., McDonald-McGinn, D. M., Spinner, N. B., Zackai, E. H. Submicroscopic
deletion in cousins with Prader-Willi syndrome causes a grandmatrilineal inheritance pattern: effects of imprinting. Am. J. Med. Genet.
92: 19-24, 2000. [PubMed: 10797418, related citations] [Full Text: John Wiley & Sons, Inc.]
154. Mitchell, M., Schinzel, A., Langlois, S., Gillessen-Kaesbach, G., Schuffenhauer, S., Michaelis, R., Abeliovich, D., Lerer, I., Christian, S., Guitart, M.,
McFadden, D. E., Robinson, W. P. Comparison of phenotype in uniparental disomy and deletion Prader-Willi syndrome. Am. J. Med. Genet
65: 133-136, 1996. [PubMed: 8911605, related citations]
155. Mogul, H. R., Lee, P. D. K., Whitman, B. Y., Zipf, W. B., Frey, M., Myers, S., Cahan, M., Pinyerd, B., Southren, A. L. Growth hormone treatment
of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum
triiodothyronine without glucose impairment: results from the United States multicenter trial. J. Clin. Endocr. Metab. 93: 1238-1245, 2008.
156. Muscatelli, F., Abrous, D. N., Massacrier, A., Boccaccio, I., Le Moal, M., Cau, P., Cremer, H. Disruption of the mouse Necdin gene results in
hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum. Molec. Genet. 9: 3101-3110, 2000.
157. Mutirangura, A., Greenberg, F., Butler, M. G., Malcolm, S., Nicholls, R. D., Chakravarti, A., Ledbetter, D. H. Multiplex PCR of three dinucleotide
repeats in the Prader-Willi/Angelman critical region (15q11-q13): molecular diagnosis and mechanism of uniparental disomy. Hum.
Molec. Genet. 2: 143-151, 1993. [PubMed: 8499903, related citations] [Full Text: HighWire Press]
158. Nagai, T., Matsuo, N., Kayanuma, Y., Tonoki, H., Fukushima, Y., Ohashi, H., Murai, T., Hasegawa, T., Kuroki, Y., Niikawa, N. Standard growth
curves for Japanese patients with Prader-Willi syndrome. Am. J. Med. Genet. 95: 130-134, 2000. [PubMed: 11078562, related citations] [Full
Text: John Wiley & Sons, Inc.]
159. Nakatsu, Y., Gondo, Y., Brilliant, M. H. The p locus is closely linked to the mouse homolog of a gene from the Prader-Willi chromosomal
region. Mammalian Genome 2: 69-71, 1992. [PubMed: 1347469, related citations]
160. Nicholls, R. D., Knoll, J. H. M., Butler, M. G., Karam, S., Lalande, M. Genetic imprinting suggested by maternal heterodisomy in non-deletion
Prader-Willi syndrome. Nature 342: 281-285, 1989. [PubMed: 2812027, related citations] [Full Text: Nature Publishing Group]
161. Nicholls, R. D., Knoll, J. H. M., Butler, M. G., Korum, S., Shook, D., Glatt, K., Lalande, M. Uniparental disomy for chromosome 15 in the Prader-
Willi syndrome. (Abstract) Am. J. Hum. Genet. 45 (suppl.): A209 only, 1989.
162. Ohta, T., Gray, T. A., Rogan, P. K., Buiting, K., Gabriel, J. M., Saitoh, S., Muralidhar, B., Bilienska, B., Krajewska-Walasek, M., Driscoll, D. J.,
Horsthemke, B., Butler, M. G., Nicholls, R. D. Imprinting-mutation mechanisms in Prader-Willi syndrome. Am. J. Hum. Genet. 64: 397-413,
1999. [PubMed: 9973278, related citations] [Full Text: Elsevier Science]
163. Oiglane-Shlik, E., Zordania, R., Varendi, H., Antson, A., Magi, M.-L., Tasa, G., Bartsch, O., Talvik, T., Ounap, K. The neonatal phenotype of
Prader-Willi syndrome. Am. J. Med. Genet. 140A: 1241-1244, 2006. [PubMed: 16642508, related citations] [Full Text: John Wiley & Sons, Inc.]
164. Olander, E., Stamberg, J., Steinberg, L., Wulfsberg, E. A. Third Prader-Willi syndrome phenotype due to maternal uniparental disomy 15
with mosaic trisomy 15. Am. J. Med. Genet. 93: 215-218, 2000. [PubMed: 10925385, related citations] [Full Text: John Wiley & Sons, Inc.]
165. Orenstein, D. M., Boat, T. F., Owens, R. P., Horowitz, J. G., Primiano, F. P., Germann, K., Doershuk, C. F. The obesity hypoventilation syndrome
in children with the Prader-Willi syndrome: a possible role for familial decreased response to carbon dioxide. J. Pediat. 97: 765-767, 1980.
166. Orstavik, K. H., Tangsrud, S. E., Kiil, R., Hansteen, I.-L., Steen-Johnsen, J., Cassidy, S. B., Martony, A., Anvret, M., Tommerup, N., Brondum-Nielsen,
K. Prader-Willi syndrome in a brother and sister without cytogenetic or detectable molecular genetic abnormality at chromosome
15q11q13. Am. J. Med. Genet. 44: 534-538, 1992. [PubMed: 1442901, related citations]
167. Ozcelik, T., Leff, S., Robinson, W., Donlon, T., Lalande, M., Sanjines, E., Schinzel, A., Francke, U. Small nuclear ribonucleoprotein polypeptide
N (SNRPN), an expressed gene in the Prader-Willi syndrome critical region. Nature Genet. 2: 265-269, 1992. [PubMed: 1303277, related
citations] [Full Text: Nature Publishing Group]
168. Park, J. P., Moeschler, J. B., Hani, V. H., Hawk, A. B., Belloni, D. R., Noll, W. W., Mohandas, T. K. Maternal disomy and Prader-Willi syndrome
consistent with gamete complementation in a case of familial translocation (3;15)(p25;q11.2). Am. J. Med. Genet. 78: 134-139, 1998. [PubMed:
9674903, related citations] [Full Text: John Wiley & Sons, Inc.]
169. Phelan, M. C., Albiez, K. L., Flannery, D. B., Stevenson, R. E. The Prader-Willi syndrome and albinism in a black infant. Proc. Greenwood
Genet. Center 7: 27-29, 1988.
170. Prader, A. Personal Communication. Zurich, Switzerland 1991.
171. Prader, A., Labhart, A., Willi, H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach Myatonieartigem
Zustand im Neugeborenenalter. Schweiz. Med. Wschr. 86: 1260-1261, 1956.
172. Purvis-Smith, S. G., Saville, T., Manass, S., Yip, M.-Y., Lam-Po-Tang, P. R. L., Duffy, B., Johnston, H., Leigh, D., McDonald, B. Uniparental
disomy 15 resulting from 'correction' of an initial trisomy 15. (Letter) Am. J. Hum. Genet. 50: 1348-1350, 1992. [PubMed: 1598916, related
citations]
173. Qumsiyeh, M. B., Dalton, J. D., Gordon, P. L., Wilroy, R. S., Tharapel, A. T. Deletion of chromosome 15pter-q11.2 due to t(Y;15) in a boy with
Prader-Willi syndrome. Am. J. Med. Genet. 42: 109-111, 1992. [PubMed: 1308348, related citations]
174. Reed, M. L., Leff, S. E. Maternal imprinting of human SNRPN, a gene deleted in Prader-Willi syndrome. Nature Genet. 6: 163-167, 1994.
[PubMed: 7512861, related citations] [Full Text: Nature Publishing Group]
175. Reed, T., Butler, M. G. Dermatoglyphic features in Prader-Willi syndrome with respect to chromosomal findings. Clin. Genet. 25: 341-346,
176. Ridler, M. A. C., Gerrod, O., Berg, J. M. A case of Prader-Willi in a girl with a small extra chromosome. Acta Paediat. Scand. 60: 222-226, 1971.
177. Rinchik, E. M., Bultman, S. J., Horsthemke, B., Lee, S. T., Strunk, K. M., Spritz, R. A., Avidano, K. M., Jong, M. T. C., Nicholls, R. M. A gene for the
mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature 361: 72-76, 1993. [PubMed: 8421497, related
citations] [Full Text: Nature Publishing Group]
178. Rivera, H., Zuffardi, O., Gargantini, L. Nonreciprocal and jumping translocations of 15q1-qter in Prader-Willi syndrome. Am. J. Med. Genet.
37: 311-317, 1990. [PubMed: 2260556, related citations]
179. Robinson, W. P., Bernasconi, F., Mutirangura, A., Ledbetter, D. H., Langlois, S., Malcolm, S., Morris, M. A., Schinzel, A. A. Nondisjunction of
chromosome 15: origin and recombination. Am. J. Hum. Genet. 53: 740-751, 1993. [PubMed: 8352279, related citations]
180. Robinson, W. P., Binkert, F., Gine, R., Vazquez, C., Mueller, W., Rosenkranz, W., Schinzel, A. Clinical and molecular analysis of five inv dup(15)
patients. Europ. J. Hum. Genet. 1: 37-50, 1993. [PubMed: 8069650, related citations]
181. Robinson, W. P., Bottani, A., Yagang, X., Balakrishman, J., Binkert, F., Machler, M., Prader, A., Schinzel, A. Molecular, cytogenetic, and clinical
investigations of Prader-Willi syndrome patients. Am. J. Hum. Genet. 49: 1219-1234, 1991. [PubMed: 1684085, related citations]
182. Robinson, W. P., Lorda-Sanchez, I., Malcolm, S., Langlois, S., Schuffenhauer, S., Knoblauch, H., Horsthemke, B., Schinzel, A. A. Increased parental
ages and uniparental disomy 15: a paternal age effect? Europ. J. Hum. Genet. 1: 280-286, 1993. [PubMed: 8081941, related citations]
183. Robinson, W. P., Wagstaff, J., Bernasconi, F., Baccichetti, C., Artifoni, L., Franzoni, E., Suslak, L., Shih, L. Y., Aviv, H., Schinzel, A. A. Uniparental
disomy explains the occurrence of the Angelman or Prader-Willi syndrome in patients with an additional small inv dup(15)
chromosome. J. Med. Genet. 30: 756-760, 1993. [PubMed: 8411071, related citations] [Full Text: HighWire Press]
184. Runte, M., Varon, R., Horn, D., Horsthemke, B., Buiting, K. Exclusion of the C/D box snoRNA gene cluster HBII-52 from a major role in
Prader-Willi syndrome. Hum. Genet. 116: 228-230, 2005. [PubMed: 15565282, related citations] [Full Text: Springer]
185. Sahoo, T., del Gaudio, D., German, J. R., Shinawi, M., Peters, S. U., Person, R. E., Garnica, A., Cheung, S. W., Beaudet, A. L. Prader-Willi
phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nature Genet. 40: 719-721, 2008. [PubMed:
18500341, related citations] [Full Text: Nature Publishing Group]
186. Schinzel, A. Approaches to the prenatal diagnosis of the Prader-Willi syndrome. (Letter) Hum. Genet. 74: 327 only, 1986. [PubMed: 3781563,
related citations]
187. Schinzel, A., Robinson, W. P., Bottani, A., Yagang, X., Prader, A. Prader-Willi or Angelman syndrome in familial 15q11-q13 deletion of
maternal origin? Hum. Genet. 88: 361-362, 1992. [PubMed: 1733842, related citations]
188. Schulze, A., Hansen, C., Skakkebaek, N. E., Brondum-Nielsen, K., Ledbetter, D. H., Tommerup, N. Exclusion of SNRPN as a major determinant
of Prader-Willi syndrome by a translocation breakpoint. Nature Genet. 12: 452-454, 1996. [PubMed: 8630505, related citations] [Full Text:
Nature Publishing Group]
189. Seyler, L. E., Jr., Arulanantham, K., O'Connor, C. F. Hypergonadotropic-hypogonadism in the Prader-Labhart-Willi syndrome. J. Pediat. 94:
190. Sinnema, M., Schrander-Stumpel, C. T. R. M., Maaskant, M. A., Boer, H., Curfs, L. M. G. Aging in Prader-Willi syndrome: twelve persons over
the age of 50 years. Am. J. Med. Genet. 158A: 1326-1336, 2012. [PubMed: 22585395, related citations] [Full Text: John Wiley & Sons, Inc.]
191. Smeets, D. F. C. M., Hamel, B. C. J., Nelen, M. R., Smeets, H. J. M., Bollen, J. H. M., Smits, A. P. T., Ropers, H.-H., van Oost, B. A. Prader-Willi
syndrome and Angelman syndrome in cousins from a family with a translocation between chromosomes 6 and 15. New Eng. J. Med. 326:
807-811, 1992. [PubMed: 1538725, related citations] [Full Text: Atypon]
192. Smith, A., Jauch, A., Slater, H., Robson, L., Sandanam, T. Syndromal obesity due to paternal duplication 6(q24.3-q27). Am. J. Med. Genet. 84:
125-131, 1999. [PubMed: 10323737, related citations] [Full Text: John Wiley & Sons, Inc.]
193. Smith, A., Lindeman, R., Volpato, F., Kearney, A., White, S., Haan, E., Trent, R. J. A de novo unbalanced reciprocal translocation identified as
paternal in origin in the Prader-Willi syndrome. Hum. Genet. 86: 534-536, 1991. [PubMed: 2016095, related citations]
194. Smith, A., Murray, R., den Dulk, G. Familial deletion. Ann. Genet. (Paris) 26: 91-93, 1983.
195. Smith, A., Noel, M. A girl with the Prader-Willi syndrome and Robertsonian translocation 45,XX,t(14;15)(p11;q11) which was present in
three normal family members. Hum. Genet. 55: 271-273, 1980. [PubMed: 7450770, related citations]
196. Stein, C. K., Stred, S. E., Thomson, L. L., Smith, F. C., Hoo, J. J. Interstitial 6q deletion and Prader-Willi-like phenotype. Clin. Genet. 49: 306-
197. Stephenson, J. B. P. Prader-Willi syndrome: neonatal presentation and later development.. Dev. Med. Child Neurol. 22: 792-795, 1980.
198. Strakowski, S. M., Butler, M. G. Paternal hydrocarbon exposure in Prader-Willi syndrome. (Letter) Lancet 33: 1458 only, 1987. Note:
Originally Volume II. [PubMed: 2892013, related citations]
199. Sutcliffe, G. S. Personal Communication. Oxford, England 1994.
200. Tommerup, N. Personal Communication. Zurich, Switzerland 1993.
201. Trent, R. J., Volpato, F., Smith, A., Lindeman, R., Wong, M.-K., Warne, G., Haan, E. Molecular and cytogenetic studies of the Prader-Willi
syndrome. J. Med. Genet. 28: 649-654, 1991. [PubMed: 1682493, related citations] [Full Text: HighWire Press]
202. van Mil, E. G. A. H., Westerterp, K. R., Gerver, W.-J. M., Van Marken Lichtenbelt, W. D., Kester, A. D. M., Saris, W. H. M. Body composition in
Prader-Willi syndrome compared with nonsyndromal obesity: relationship to physical activity and growth hormone function. J. Pediat.
139: 708-714, 2001. [PubMed: 11713451, related citations] [Full Text: Elsevier Science]
203. Veenema, H., Beverstock, G. C., Zvelebil-Tarasevitch, N., Doorn, J. L., van Parys, J. A. P., van de Kamp, J. J. P. Duplication in the proximal
portion of the long arm of chromosome 15, in a girl without phenotypic features of the Prader-Willi syndrome. Clin. Genet. 26: 65-68,
204. Villa, A., Urioste, M., Bofarull, J. M., Martinez-Frias, M. L. De novo interstitial deletion q16.2q21 on chromosome 6. Am. J. Med. Genet. 55: 379-
205. Vogels, A., De Hert, M., Descheemaeker, M. J., Govers, V., Devriendt, K., Legius, E., Prinzie, P., Fryns, J. P. Psychotic disorders in Prader-Willi
syndrome. Am. J. Med. Genet. 127A: 238-243, 2004. [PubMed: 15150773, related citations] [Full Text: John Wiley & Sons, Inc.]
206. Warkany, J. Personal Communication. Cincinnati, Oh. 1970.
207. Wevrick, R., Francke, U. Diagnostic test for the Prader-Willi syndrome by SNRPN expression in blood. Lancet 348: 1068-1069, 1996.
[PubMed: 8874459, related citations] [Full Text: Elsevier Science]
208. Wevrick, R., Kerns, J. A., Francke, U. Identification of a novel paternally expressed gene in the Prader-Willi syndrome region. Hum. Molec.
Genet. 3: 1877-1882, 1994. [PubMed: 7849716, related citations] [Full Text: HighWire Press]
209. Wey, E., Bartholdi, D., Riegel, M., Nazlican, H., Horsthemke, B., Schinzel, A., Baumer, A. Mosaic imprinting defect in a patient with an almost
NOTE: OMIM is intended for use primarily by phy sicians and other professionals concerned with genetic disorders, by genetics researchers, and by adv anced students in science and medicine. While the OMIM database
is open to the public, users seeking information about a personal medical or genetic condition are urged to consult with a qualified phy sician for diagnosis and for answers to personal questions.
OMIM
and Online Mendelian Inheritance in Man
are registered trademarks of the Johns Hopkins Univ ersity .

Copy right
1966-2014 Johns Hopkins Univ ersity .

typical expression of the Prader-Willi syndrome. Europ. J. Hum. Genet. 13: 273-277, 2005. [PubMed: 15578038, related citations] [Full Text:
Nature Publishing Group]
210. Wharton, R. H., Wang, T., Graeme-Cook, F., Briggs, S., Cole, R. E. Acute idiopathic gastric dilatation with gastric necrosis in individuals with
Prader-Willi syndrome. Am. J. Med. Genet. 73: 437-441, 1997. [PubMed: 9415471, related citations] [Full Text: John Wiley & Sons, Inc.]
211. White, L. M., Rogan, P. K., Nicholls, R. D., Wu, B.-L., Korf, B., Knoll, J. H. M. Allele-specific replication of 15q11-q13 loci: a diagnostic test for
detection of uniparental disomy. Am. J. Hum. Genet. 59: 423-430, 1996. [PubMed: 8755930, related citations]
212. Whittington, J., Holland, A., Webb, T., Butler, J., Clarke, D., Boer, H. Relationship between clinical and genetic diagnosis of Prader-Willi
syndrome. (Letter) J. Med. Genet. 39: 926-932, 2002. [PubMed: 12471208, related citations] [Full Text: HighWire Press]
213. Whittington, J. E., Holland, A. J., Webb, T., Butler, J., Clarke, D., Boer, H. Population prevalence and estimated birth incidence and mortality
rate for people with Prader-Willi syndrome in one UK Health Region.(Letter) J. Med. Genet. 38: 792-798, 2001. [PubMed: 11732491, related
214. Wiesner, G. L., Bendel, C. M., Olds, D. P., White, J. G., Arthur, D. C., Ball, D. W., King, R. A. Hypopigmentation in the Prader-Willi syndrome.
Am. J. Hum. Genet. 40: 431-442, 1987. [PubMed: 3578281, related citations]
215. Williams, M. S., Rooney, B. L., Williams, J., Josephson, K., Pauli, R. Investigation of thermoregulatory characteristics in patients with Prader-
Willi syndrome. Am. J. Med. Genet. 49: 302-307, 1994. [PubMed: 8209890, related citations]
216. Wirth, J., Back, E., Huttenhofer, A., Nothwang, H.-G., Lich, C., Gross, S., Menzel, C,, Schinzel, A., Kioschis, P., Tommerup, N., Ropers, H.-H.,
Horsthemke, B., Buiting, K. A translocation breakpoint cluster disrupts the newly defined 3-prime end of the SNURF-SNRPN
transcription unit on chromosome 15. Hum. Molec. Genet. 10: 201-210, 2001. [PubMed: 11159938, related citations] [Full Text: HighWire Press]
217. Wise, M. S., Zoghbi, H., Edwards, M., Byrd, L. K., Guttmacher, A. E., Greenberg, F. Hyperthermia in infants with Prader-Willi syndrome.
(Abstract) Am. J. Med. Genet. 41: 528 only, 1991.
218. Wisniewski, L. P., Witt, M. E., Ginsberg-Fellner, F., Wilner, J., Desnick, R. J. Prader-Willi syndrome and a bisatellited derivative of
chromosome 15. Clin. Genet. 18: 42-47, 1980. [PubMed: 7418253, related citations]
219. Woodage, T., Lindeman, R., Deng, Z. M., Fimmel, A., Smith, A., Trent, R. J. Physical mapping studies at D15S10: implications for candidate
gene identification in the Angelman syndrome/Prader-Willi syndrome chromosome region of 15q11-q13.. Genomics 19: 170-172, 1994.
[PubMed: 8188222, related citations] [Full Text: Elsevier Science]
220. Xin, Z., Allis, C. D., Wagstaff, J. Parent-specific complementary patterns of histone H3 lysine 9 and H3 lysine 4 methylation at the Prader-
Willi syndrome imprinting center. Am. J. Hum. Genet. 69: 1389-1394, 2001. [PubMed: 11592036, related citations] [Full Text: Elsevier Science]
221. Yang, T., Adamson, T. E., Resnick, J. L., Leff, S., Wevrick, R., Francke, U., Jenkins, N. A., Copeland, N. G., Brannan, C. I. A mouse model for
Prader-Willi syndrome imprinting-centre mutations. Nature Genet. 19: 25-31, 1998. [PubMed: 9590284, related citations] [Full Text: Nature
Publishing Group]
222. Zellweger, H., Schneider, H. J. Syndrome of hypotonia-hypomentia-hypogonadism-obesity (HHHO) or Prader-Willi syndrome. Am. J. Dis.
Child. 115: 588-598, 1968. [PubMed: 5645106, related citations] [Full Text: HighWire Press]
223. Zori, R., Williams, C., Mattei, J. F., Moncla, A. Parental origin of del(15)(q11-q13) in Angelman and Prader-Willi syndromes.. Am. J. Med.
224. Zuffardi, O., Buhler, E. M., Fraccaro, M. Chromosome 15 and Prader-Willi syndrome. (Abstract) Clin. Genet. 14: 315-316, 1978.
Contributors: Ada Hamosh - updated : 3/27/2014
Creation Date: Victor A. McKusick : 6/2/1986
Edit History: mcolton : 05/07/2014

OMIM Entry - # 176270 - PRADER-WILLI SYNDROME PWS PDF

Transféré par

Informations du document

Description originale:

Titre original

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

OMIM Entry - # 176270 - PRADER-WILLI SYNDROME PWS PDF

Transféré par

Droits d'auteur :

Formats disponibles

27/5/2014 OMIM Entry - # 176270 - PRADER-WILLI SYNDROME; PWS

and Online Mendelian Inheritance in Man

are registered trademarks of the Johns Hopkins Univ ersity .

1966-2014 Johns Hopkins Univ ersity .

Vous aimerez peut-être aussi